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C-JUN N-TERMINAL KINASES REGULATE ADENOVIRUS-
MEDIATED AUTOPHAGY AND ANTIGEN PRESENTATION  
 
Sarah Renee Klein, B.S. 
Supervisory Professor: Juan Fueyo, M.D. 
 
Targeted immunotherapy with recombinant, oncolytic adenoviruses is under 
investigation for the treatment of cancer. Evidence indicates adenoviruses induce autophagy 
that is required for oncolysis, but the molecular regulation of autophagy in infected cells 
remains under investigation. Our data suggested the canonical pathway regulating starvation-
induced autophagy was not implemented in adenovirus-induced autophagy; however, 
adenovirus infection triggered phosphorylation of c-Jun N-terminal kinases (JNK) that was 
essential for autophagy. Adenoviral replication within the host cell elicited JNK pathway 
activation leading to B cell lymphoma-2 (Bcl-2) phosphorylation. JNK-dependent Bcl-2 
phosphorylation stimulated the dissociation of Bcl-2/beclin 1 heterodimers, enabling beclin 1 to 
initiate autophagy. Moreover, phosphorylation of both JNK and Bcl-2 was observed in human 
glioma xenografts after infection with the oncolytic, tropism-enhanced Delta-24-RGD 
adenovirus, which is currently under investigation in a clinical trial for the treatment of 
recurring malignant gliomas. Contrary to starvation-induced autophagy, inhibiting adenovirus-
mediated autophagy requires genetic knock-out of both JNK1 and JNK2 isoforms, suggesting 
these proteins have overlapping roles for regulating autophagy in infected cells. Therefore, we 
report a unique mechanism for the regulation of adenovirus-mediated autophagy that differs 
from the conventional paradigm.  
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Adenoviruses are highly immunogenic; and thus, potentially useful vectors for 
immunotherapeutic strategies. Importantly, autophagy promotes the presentation of self and 
foreign antigens for activation of immune cells. Our data demonstrated for the first time that 
adenoviral epitopes were presented at the surface of cells through JNK- and autophagy-
dependent mechanisms. Rapamycin, a chemical activator of autophagy, was able to enhance 
adenoviral antigen presentation. This investigation proposes JNK signaling and autophagy 
promote adenoviral antigen presentation to the immune system which can be leveraged in 
developing recombinant adenoviruses for the advancement of anti-tumor immunotherapy. With 
this knowledge, we developed a novel adenovirus expressing the immunogenic, tumor-specific 
epidermal growth factor receptor variant III (EGFRvIII) peptide inserted in the adenoviral fiber 
protein. We confirmed that the EGFRvIII epitope was displayed at the surface of cells in an 
autophagy-dependent manner that could be enhanced by the pro-inflammatory cytokine, 
interferon gamma. Thus, we established a new mechanism for the regulation of adenovirus-
mediated autophagy and antigen presentation that we employed for the advancement of 
adenovirus-based vaccines. 
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Chapter I: Background and Significance 
 
Adenoviruses 
 Adenoviruses, otherwise known as the common cold, were discovered in the 1950s 
upon being isolated from adenoid tissue (Rowe etal., 1953). They are the largest non-
enveloped DNA virus, composed of an icosahedral capsid encompassing a linear, non-
segmented double stranded DNA genome. There are 51 different serotypes of adenovirus in the 
family Adenoviridae (Russell, 2009). Adenoviruses attach to the host cell through interaction 
between the knob domain of the adenoviral fiber and the coxsackie adenovirus receptor (CAR) 
on the cell surface (Roelvink et al., 1998). The adenoviral penton bases in the capsid then 
promote internalization through interaction with αv integrins (Figure 1A) (Wickham et al., 
1993). Once inside the cell, the viral DNA is transported to the cell nucleus for replication and 
transcription of viral RNA.  
Depending on the class and serotype, the size of the DNA genome can be between 26 
and 45 thousand base pairs (Kpb) in length (Russell, 2009). The genome for one of the most 
well-described serotypes, adenovirus class C serotype 5 (Ad5), is approximately 36 Kbp 
(Chroboczek et al., 1992). The Ad5 genome is made up of four early genes (E1-E4) and five 
late genes (L1-L5) (Figure 1B). The early genes are primarily involved in regulating adenovirus 
replication and controlling the host cell functions, while the late genes include structural 
proteins required for assembly. For example, the first protein expressed is early 1 A (E1A) 
which is required for transcription of the viral DNA; and thus, required for viral replication and 
production as well as counteracting antiviral cellular processes (Nevins et al., 1979; Bayley and 
Mymryk, 1994). Conversely, the structural proteins hexon and fiber are encoded by L3 and L5 
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Figure 1. The adenovirus structure and genome. A, It is a non-enveloped virus; the coat is 
made up of numerous proteins. The fiber protein assists the virus to enter the cell via the 
coxsackie adenovirus receptor. The penton base interacts with integrins for internalization of 
the virus. B, Adenoviruses have a linear, double stranded DNA genome. The first gene 
expressed is E1A, followed by all the early genes (E1B-E4, L1) required for adenoviral 
replication and manipulation of particular cellular processes. The late genes (L1-L5) are mainly 
involved in assembly. 
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genes, respectively (Russell, 2009). The early gene transcripts can be detected in the cell within 
a few hours; however, the entire adenoviral reproductive cycle is about 36 hours (Challberg 
and Kelly, 1979; Nevins et al., 1979). Upon assembly, adenoviruses express the adenovirus 
death protein (E3-11.6K) in order to lyse the cells allowing for their release and dissemination 
(Tollefson et al., 1996).  
 
Adenoviruses and cancer 
 Adenoviruses have been investigated for their potential as anti-cancer therapeutics since 
their discovery in the 1950s. During that time, several clinical trials were initiated 
administering adenoviruses into patients with the expectation of tumor cell lysis leading to 
improved clinical outcomes (Huebner et al., 1956; Southam, 1960; Webb et al., 1966; Asada, 
1974; Webb et al., 1975; Okuno et al., 1978). The results of these studies showed very little 
therapeutic benefit; therefore, exploration of adenoviruses for the treatment of cancer came to a 
halt. However, since then investigators have expanded upon the knowledge and tools needed to 
manipulate the adenoviral genome, and more recent studies have begun using targeted, 
conditionally-replicating adenoviruses for the treatment of cancer (Martuza et al., 1991; 
Khuri et al., 2000; Reid et al., 2002). Many of these trials involved an adenovirus mutant for 
either the E1A or E1B gene products. E1A competitively binds to Rb, resulting in release of the 
transcription factor E2F and consequent cell cycle initiation. E1B55K binds to and inactivates 
p53, preventing cell cycle arrest and apoptosis. Nearly all tumors possess defects in their p53 
and/or Rb pathways. Thus, E1A- or E1B-mutated adenoviruses can still replicate in Rb- or p53-
defective tumor cells, respectively; however, replication of these mutated viruses is attenuated 
in normal cells where these pathways remain intact (Everts and van der Poel, 2005). 
 In addition to conditional replication, adenoviruses have been genetically modified to 
broaden their tropism in order to enhance infectivity in cancer cells that express low levels of 
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CAR (Miller et al., 1998; Barnett et al., 2002). The most common involves the addition of a 
RGD-4C (CDCRGDCFC) peptide inserted into the HI loop of adenoviral fiber, which allows 
the virus to infect cells by binding integrins with a higher affinity (Krasnykh et al., 1998; Fueyo 
et al., 2003). Once adenoviruses have been engineered to selectively infect and replicate within 
cancer cells, they can further be altered to express therapeutic genes such as tumor suppressors 
p53 or PTEN (Köck et al., 1996; Li et al., 2013), or express tumor-associated antigens for 
potential anti-tumor immune activation (Cho et al., 2003; Zeng et al., 2011). 
 
Malignant gliomas 
Gliomas account for 80% of all malignant, primary brain and CNS tumors, making 
them the most common and invasive form of brain tumor in adults. Therapeutic options are still 
very limited with first-line treatment combining surgery, radiotherapy and adjuvant 
chemotherapy (temozolomide). Regardless of treatment, this disease is invariably fatal with a 
median survival that remains at only 12-15 months after initial diagnosis (Central Brain Tumor 
Registry of the US, 2004-7). Gliomas are refractory to current surgical and radiotherapeutic 
treatments, and the blood-brain barrier provides a considerable obstacle for systemic 
chemotherapy. Consequently, conditionally-replicating, oncolytic viruses are being examined 
as a more effective mode for targeted treatment of patients with malignant gliomas (Sonabend 
et al, 2006; Jiang et al., 2009).  
 
Delta-24-RGD from bench to bedside 
Our laboratory is focused on the development and optimization of adenoviruses that can 
be employed as therapy for malignant gliomas. Delta-24-RGD (∆24RGD) is a tropism-
enhanced, oncolytic adenovirus that is under clinical investigation for the treatment of recurring 
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gliomas (Fueyo et al, 2000; Fueyo et al, 2003; ongoing clinical trial). This adenovirus is a 
genetically altered form of the parental adenovirus type 5 that incorporates the following two 
modifications: 1) a 24-base pair deletion in the E1A gene sequence which allows the adenovirus 
to replicate selectively and efficiently in tumor cells that have an inactivated Rb pathway 
(Fueyo et al., 2000); and 2) a RGD-4C peptide insertion which causes the adenovirus to have a 
higher affinity to integrins for their internalization (Fueyo et al., 2003; Jiang et al., 2007). The 
Cancer Genome Atlas Project has unequivocally demonstrated that the Rb pathway is abnormal 
in at least 75% of malignant gliomas (The Cancer Genome Atlas Research Network, 2008). In 
addition, glioma cells express high levels of integrins (Gladson and Cheresh, 1991; Miller et 
al., 1998); thus, ∆24RGD is a highly selective, highly potent oncolytic virus for the treatment 
of this devastating disease. Currently, ∆24RGD is being tested in a Phase I clinical trial in 
patients with recurring gliomas at The University of Texas - M. D. Anderson Cancer Center. 
Importantly, previous research in our laboratory demonstrates that glioma cells and brain tumor 
stem cells infected with ∆24RGD undergo autophagy that is required for tumor cell lysis (Jiang 
et al, 2007; Jiang et al, 2011). There is accumulating evidence that adenovirus infection results 
in the induction of dramatic autophagy in the host cells (Ito et al, 2006; Baird et al, 2008; Piya 
et al, 2011); however, there is a paucity of information regarding the main regulatory pathways 
controlling autophagy in adenovirus-infected cells.  
 
Adenoviruses and autophagy 
Autophagy is a tightly regulated program for the degradation of long-lived proteins, 
cytoplasmic organelles, and intracellular pathogens to maintain cellular homeostasis (Klionsky 
et al., 2000). Autophagy occurs in response to nutrient deprivation and other types of cellular 
stress and damage (Kroemer et al., 2010). It is a mechanism of both cell survival and cell death; 
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although how these processes are differentiated at the molecular level is not yet characterized 
(Codogno and Meijer, 2005). Evidence indicates that host cells undergo autophagy during 
adenovirus infection (Ito et al., 2006; Jiang et al., 2007; Jiang et al., 2011; Piya et al., 2011). 
Viruses have been known to utilize autophagy to prolong host cell survival for the production 
of viral particles, followed by autophagic cell death for their release (Taylor and Kirkegaard, 
2008; Lee et al, 2008; Ait-Goughoulte, 2008; Zhou et al, 2009). The signal transduction and 
molecular interactions involved in the induction and maintenance of adenovirus-mediated 
autophagy remain elusive. We have previously reported that adenoviral protein E1B19K can 
interact with beclin 1, a key effector of autophagy (Piya et al., 2011). Although our results 
indicate a role for E1B19K in the maintenance of adenovirus-mediated autophagy, the 
genetically-modified virus lacking E1B19K was able to induce moderate autophagy. Therefore 
further investigation into the mechanism of autophagy after adenovirus infection is required. 
 
Signaling pathways in autophagy 
The accepted paradigm of autophagy regulation is represented by a series of molecular 
and cellular processes described in starving cells (Noda and Ohsumi 1998; Inoki et al, 2002; 
Inoki et al, 2003). A decrease in intracellular ATP due to starvation or stress conditions results 
in phosphorylation of adenosine monophosphate-activated protein kinases (AMPK) (Hardie, 
2004). AMPKs phosphorylate tuberous sclerosis protein 2 (TSC2), which inactivates 
mammalian target of rapamycin (mTOR) (Inoki et al., 2003; Kim et al., 2011). Mammalian 
TOR is a pivotal negative regulator of autophagy (Noda and Ohsumi, 1998). In contrast, AKT 
phosphorylates mTOR in response to growth factor and nutrient stimulation resulting in 
inhibition of autophagy (Inoki et al., 2002). Thus, the AKT signaling directs the cell to halt 
recycling of cellular components via autophagy, and initiates transcription and cell proliferation 
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Figure 2. The archetypal signaling pathway regulating the induction of autophagy. AMPK 
are activated by numerous stimuli, including starvation. AMPKs phosphorylate TSC2 which 
inhibits mTOR, thus allowing autophagy to proceed. AKT is also phosphorylated by numerous 
stimuli, including growth factors. AKT inhibits TSC2 phosphorylation; thus, AKT positively 
regulates mTOR phosphorylation and autophagy inhibition. P70S6K is a substrate of mTOR 
that leads to transcription. 
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through activation of mTOR and the downstream substrate p70S6K (Jefferies et al., 1997; 
Inoki et al., 2002). AMPK and AKT function inversely to activate or inhibit autophagy, 
respectively, through TSC2. As such, AKT inactivates TSC2, permitting mTOR to inhibit 
autophagy (Inoki et al., 2002). (Figure 2) 
These initial interactions induce or inhibit autophagy by influencing downstream 
effectors such as beclin 1 and microtubule-associated protein 1A/1B-light chain 3 (LC3). 
Beclin 1 is part of a complex that initiates nucleation of the isolation membrane from the ER 
(Figure 3) (Kihara et al., 2001). LC3-I protein is lipidated and cleaved to form LC3-II, and 
LC3-II is inserted into the autophagosomal membrane to assist in elongation (Mizushima et al., 
2001). Simultaneously, p62 recruits ubiquitinated protein aggregates, damaged organelles, and 
intracellular pathogens to be engulfed by the autophagosomal membrane (Pankiv et al., 2007; 
Levine et al., 2011). The contents are degraded upon fusion of autophagosomes with 
lysosomes, and metabolic precursors are recycled by the cell (Figure 3).  Importantly, 
autophagy can be detected experimentally by these molecular and morphological phenomena: 
1) lipidation and cleavage of LC3-I to LC3-II; 2) selective degradation of the p62; and 3) 
visualization of double membrane-bound autophagic vacuoles by electron microscopy 
(Mizushima et al., 2010).  
Beclin 1 was originally isolated and identified as a B cell lymphoma/leukemia-2 (Bcl-2) 
interacting protein (Liang et al., 1999). Bcl-2 binds to beclin 1, blocking the interaction of 
beclin 1 with phosphatidylinositol 3 kinase class 3 (Pi3KC3) thereby preventing initiation of 
autophagy (Itakura et al., 2008). Importantly, recent studies on starvation-induced autophagy 
demonstrated that the mitogen–activated protein (MAP) kinase c-Jun N-terminal kinase 1 
(JNK1) phosphorylates Bcl-2 and inhibits its ability to interact with beclin 1, thereby 
facilitating autophagy (Wei et al, 2008). The nature of JNK-mediated phosphorylation of Bcl-2 
remains under investigation and has not been addressed in adenovirus-induced autophagy. 
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Figure 3. The molecular events characteristic of autophagy. The beclin 1 complex initiates 
nucleation of the isolation membrane. LC3-I is cleaved and lipidated forming LC3-II, which is 
inserted into the membrane for assistance in elongation. P62 recruits aggregated proteins, 
damaged organelles, and foreign pathogens to the autophagosome. Autophagosomes fuse with 
lysosomes, where digestive enzymes degrade the contents into their basic components: 
peptides, lipids, carbohydrates. 
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C-Jun N-terminal kinase 
C-Jun N-terminal kinase (JNK) is a mitogen-activated protein kinase that is involved in 
numerous signal transducing networks leading to a range of cellular endpoints including cell 
proliferation, apoptosis and, most recently discovered, autophagy (Johnson and Lapadat, 2002; 
Wei et al, 2008). There are three isoforms of JNK (JNK1, JNK2, and JNK3) with increased 
variation due to alternative splicing. JNK1 and JNK2 often have redundant roles; however, 
JNK3 is expressed mainly in neurons and the heart, and is primarily involved in embryonic 
development (Martin et al., 1996; Gupta et al., 1996; Kuan et al., 1999).  
There is evidence regarding JNK activation during adenovirus infection. One team of 
investigators reported JNK was activated upon adenoviral fiber binding to the coxsackie 
adenovirus receptor on the cell surface during infection of respiratory cells (Tamanini et al., 
2003; Tamanini et al., 2006). Most of the investigations regarding adenovirus-induced JNK 
activation involve the antiviral cellular immune response. JNK has long been recognized as an 
important immune modulator in response to pathogens, including adenovirus. Recognition of 
adenoviral oligonucleotides by cellular receptors and proteins (e.g., Toll-like receptor 9 and 
retinoic acid-inducible gene 1) stimulates JNK signaling for expression of pro-inflammatory 
cytokines (Ichijo H., 1999; Johnson and Lapadat, 2002; Barton and Medzhitov, 2003; 
Minamitani et al., 2011). Furthermore, adenovirus-infected cells express and release type 1 
interferons at high levels via JNK-dependent and independent pathways (Basner-Tschakarjan 
et al, 2006; Minamitani et al., 2011). Interferons, the gold standard for an anti-adenoviral 
immune response, are also potent activators of JNK signal transduction leading to apoptosis 
(Ichijo et al., 1997; Caraglia et al., 1999; Sung et al, 2001; Takada et al., 2005); nevertheless, 
adenoviruses have numerous mechanisms for blocking apoptosis downstream of JNK (Rao et 
al., 1992; White, 1993). Additionally, type 1 interferons lead to the up-regulation of 2′,5′-
oligoadenylate synthetase (OAS) (Rutherford et al., 1988). OAS recognizes adenoviral double 
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stranded RNAs and produces 2'-5' linked oligoadenylates, which trigger activation of RNase L 
and consequent JNK activation (Hovanessian et al., 1977, Zhou et al., 1993; Siddiqui et al., 
2012). The canonical pro-inflammatory response to adenovirus also includes tumor necrosis 
factor-alpha (Sung et al., 2001). Tumor necrosis factor-alpha (TNFα) regulates apoptosis 
signal-regulating kinase 1 (Ask1)-dependent JNK phosphorylation via the TNF receptor-
associated factor (TRAF) 2 or 6 adapter proteins (Nishitoh et al., 1998; Yoon et al., 2008). 
Therefore, JNK phosphorylation in adenovirus-infected cells may result from a multitude of 
molecular events, triggered by both cellular and viral elements in the battle to control 
production and dissemination of the virus.  
JNK is also known to play a role in autophagy. Recent studies on starvation-induced 
autophagy demonstrated that one isoform of the JNK family, JNK1, activates autophagy 
through regulation of Bcl-2/beclin 1 interactions (Wei et al., 2008). In addition, JNKs may play 
a role in the regulation of ER stress-induced autophagy and oxidative stress-induced autophagy 
(Ogata et al., 2006; Wong et al., 2010), as well as in etoposide- and staurosporine-induced 
autophagic cell death (Shimizu et al., 2010). Moreover, the activation of JNK-dependent 
autophagy by cancer chemotherapeutic agents is currently being investigated. Resveratrol 
requires JNK to induce autophagic cell death in chronic myelogenous leukemia (Puissant et al., 
2010). The investigational compounds oridonin and bufalin also activate autophagy in cancer 
cells through JNK-dependent mechanisms (Cui et al., 2007; Xei et al., 2011). JNK has also 
even been implicated in regulating autophagy activated by insulin-like growth factor-1 and 
tumor necrosis factor-alpha signaling (Jia et al., 2006).  The link between JNK and autophagy 
is convincing; however, the molecular events involved upstream and downstream of JNK 
activation are unclear and vary among different forms of stress and stimuli. Moreover, the role 
of JNK in adenovirus-induced autophagy has not been investigated.  
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Autophagy and antigen presentation 
Autophagy is also a well-documented mechanism of immune presentation of self and 
foreign antigens (Münz et al., 2000; Paludan et al., 2005; Zhou et al., 2005; Dengjel et al., 
2005; Schmid et al., 2007; Li et al., 2008). It is an important part of the innate immune system; 
protecting cells and organisms against invasive pathogens (Levine et al., 2011). In addition to 
the direct sequestration and degradation of these pathogens, autophagy participates in the 
processing of antigens for presentation in major histocompatibility (MHC) molecules on the 
surface of virus-infected cells (Paludan et al., 2005; Crotzerand Blum, 2009; English et al., 
2009). It is also hypothesized that extracellular autophagosomes filled with foreign antigens 
will be released from the infected cell, via lytic or non-lytic processes, and may be phagocyted 
by dendritic cells leading to professional presentation of foreign antigens (Schmid et al., 2007).  
Autophagy has been implicated in the processing of viral antigens primarily for 
presentation on MHC class II molecules (Jaraquemada et al., 1990; Münz et al., 2000; 
Paludan et al., 2005). During infection with Epstein-Barr virus, the nuclear antigen 1 (EBNA1) 
is processed during autophagy, and presented on MHC class II molecules at the cell surface for 
activation of CD4+ T cells (Münz et al., 2000; Paludan et al., 2005). The same was observed 
after infection with a recombinant vaccinia virus (Jaraquemada et al., 1990). However, the role 
of autophagy in processing adenoviral antigens is currently unknown. (Figure 4) 
 
Immunotherapy in cancer 
 Anti-tumor immune activation is thought to be able to eradicate cancer 
completely. This innovative therapeutic strategy involves reprogramming the immune system 
to attack and kill tumor cells (Waldmann, 2003). Investigators hypothesize this initial attack 
will be followed by immune memory, reducing the possibility of recurrence and secondary 
tumor formation (Klebanoff et al., 2006). Immunotherapy for cancer comes in many forms.   
 - 13 - 
 
 
 
  
 
 
 
Figure 4. The role of autophagy in self and foreign antigen presentation. Protein 
aggregates, damaged organelles and intracellular pathogens are recruited to and engulfed by 
autophagosomal membranes. Autophagosomes fuse with lysosomes for degradation of the 
content by digestive enzymes. The autophagolysosomes fuse with MHC class II compartments 
(MIIC) and peptides are loaded onto MHC class II molecules for presentation to immune cells 
at the surface of the cell. 
Lysosome 
MHC class II 
Autophagosome Autophagolysosome 
MIIC
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 Adoptive immune cell therapy involves the reprogramming of a patient’s immune cells to 
target cancer cells in vitro, followed by implantation in combination with adjuvant cytokines 
for an anti-tumor immune response (Dudley et al., 2002; Phan et al., 2003). Enhanced 
activation of the immune system through the administration of cytokines (e.g. interleukin 2) has 
been examined as a therapeutic option alone, and in combination with each form of 
immunotherapy (Atkins et al., 1999). Another immunotherapeutic approach involves antibodies 
that bind to and inactivate T cell inhibitory receptors, such as cytotoxic T-lymphocyte-
associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) (Schwartz, 1992; 
Pardoll, 2012). These receptors inhibit T cell function, and are often deregulated by cancer 
cells in an attempt to evade the immune system. Thus, antibodies and peptides have been 
designed to block this mechanism, and are currently under clinical investigation for the 
treatment of various cancers (Phan et al., 2003; Brahmer et al., 2010). Most importantly, 
recombinant viruses have been investigated as anti-tumor vaccines due to the ease with which 
they can be modified to carry immune-related genes or tumor-associated antigens (Rosenberg 
et al., 1998; Bendandi et al., 1999; Gulley et al., 2002).  
 
Tumor-associated antigens in gliomas 
A tumor-associated antigen is an immunogenic peptide that is expressed selectively by 
cancer cells. Many immunotherapeutic approaches encompass tumor-associated antigens that 
are presented to the immune system in order to activate an anti-tumor immune response (Chen 
et al., 1996 Rosenberg et al., 1998; Perricone et al., 2000; Cho et al., 2003; Sorensen et al., 
2009; Zeng et al., 2011). Epidermal growth factor receptor (EGFR) is frequently up-regulated 
in cancer, particularly malignant gliomas. Moreover, the EGFR variant III (EGFRvIII) is an 
extremely prevalent, tumor-specific mutation (Moscatello et al., 1995) that is commonly 
expressed in brain tumors and brain tumor stem cells (Shinojima et al, 2003). It is also a highly 
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immunogenic protein; thus, this tumor-associated antigen has become the focus of many 
immunotherapeutic strategies for the treatment of malignant gliomas (Sampson et al., 2009). 
 
Anti-cancer vaccines 
Immune modulation using conditionally replicating, oncolytic adenoviruses is being 
examined as a more effective vehicle for the targeted treatment of cancer (Bridle et al, 2010; 
Melcher et al, 2011; Pantuck et al; 2004). The safety and immunogenicity of adenoviruses 
make them attractive for the development of vaccine platforms (Tatsis et al., 2004; Matthews, 
2011). Adenoviruses activate the innate immune system through the expression of pathogen-
associated molecular patterns and subsequent induction of the secretion of inflammatory 
cytokines. Infection is rapidly followed by the release of interleukin-6, interleukin-12, and 
tumor necrosis factor-α and accumulation of macrophages and dendritic cells in lymphatic 
tissues (Medzhitov and Janeway, 2000; Zhang et al., 2001; Schnell et al., 2001). The humoral 
immune-response includes the development of virus-neutralizing antibodies directed against 
the surface loops of the viral hexon (Wohlfart, 1988), and the penton base or the fiber (Hong et 
al., 2003). Therefore, infection by a recombinant adenovirus can prime the environment for an 
immune response against an ectopic transgene or a cancer-specific epitope inserted within the 
genome of the virus; thus, taking advantage of the cross-priming process (Carbone and Heath, 
2010). For these reasons, adenoviruses are being extensively examined as immunotherapeutic 
vectors for a broad variety of diseases including HIV and cancer (Matthews, 2011).  
The adenoviral genome is large and easily manipulated; thus, many investigators are 
developing recombinant adenoviruses expressing tumor-associated antigens in order to prime 
the environment for an immune response against tumor cells (Chen et al., 1996; Rosenberg et 
al., 1998; Perricone et al., 2000; Sorensen et al., 2009). The first FDA-approved therapeutic 
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cancer vaccine, Provenge (Sipuleucel-T) activates patient’s immune cells by professional 
antigen presentation of prostatic acid phosphatase (PAP), which is selectively over-expressed in 
most prostate cancer cells. Immunotherapy using viral vectors has already shown promising 
results for tumor suppression in certain cancers (Mellman et al, 2011; Huber et al, 2012). 
Cancer immunotherapy using oncolytic adenoviruses is an innovative means of recruiting a 
patient’s immune system to eliminate cancer. It can easily be adapted to personalized medicine, 
using the antigen expression profile of each particular patient’s tumor to determine which 
combination of recombinant adenoviruses would be best for treatment.  
 
Hypothesis and aims  
Accumulating evidence has indicated that adenoviruses induce autophagy that is required 
for host cell lysis, but the regulation of autophagy in adenoviral infected cells remains under 
investigation. We undertook this study to examine the signal transduction involved in the 
regulation of adenovirus-induced autophagy. In addition, autophagy promotes antigen 
processing and presentation at the cell surface for consequent immune cell activation. We 
intend to investigate the molecular mechanisms underlying the initiation and maintenance of 
autophagy in adenovirus-infected cells which will offer new avenues in the precise regulation 
of viral antigen presentation. Understanding the mechanisms of action by which adenoviruses 
activate cell lysis as well as how the host cell facilitates an antiviral immune response will pave 
the way for novel anti-cancer vaccines that can leverage the autophagy pathways. My central 
hypothesis is that adenovirus-infected cells demonstrate an activation of autophagy regulatory 
pathways that can be identified and characterized. One prediction of this hypothesis is that 
these signaling pathways will be required for virus-derived antigen presentation through 
autophagy. To test our hypothesis, we will investigate the components of the canonical 
pathway regulating starvation-induced autophagy, including AMP kinases, TSC2, AKT, 
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mTOR, and p70S6K. We will use wild type and recombinant human adenoviruses to infect 
human normal and cancer cell lines in order to determine the extent to which these kinases are 
active and the role they have to play in adenovirus-induced autophagy. In addition, we will 
examine the activation of the MAP kinase JNK signaling cascade in response to adenovirus 
infection in vitro and in vivo. We will determine the role of JNK activation in the regulation of 
Bcl-2/beclin 1 heterodimers, as well as discover the extent to which this pathway is required for 
adenovirus-mediated autophagy. We will establish a mechanistic continuum linking adenovirus 
infection, JNK-mediated autophagy, and adenovirus-derived antigen presentation. Lastly, we 
will develop targeted, recombinant adenoviruses expressing the EGFRvIII tumor-associated 
antigen that are presented at the host cell surface via autophagy. These novel viruses will have 
the potential to leverage their innate capacity to induce autophagy and antigen presentation, in 
order to mount an immune response against EGFRvIII-expressing malignant glioma cells. This 
unique therapeutic strategy aims to improve the currently fatal prognosis of patients suffering 
from malignant gliomas. 
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Chapter II: Materials and Methods 
 
Cell culture. MRC5 immortalized, healthy lung fibroblasts, U251 malignant glioma, HeLa 
cervical carcinoma, A549 lung carcinoma, HEK293 immortalized human embryonic kidney 
and U87  malignant glioma cell lines were obtained from the American Type Culture 
Collection. HeLa and HEK293 cells were cultured in Dulbecco's Modified Eagle Medium 
(DMEM) 1X, whereas MRC5, U251, and A549 cells were cultured in DMEM/F-12 50:50 
medium (Gibco, Invitrogen), each with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin, and incubated at 37°C in 5% CO2 in air. U87 MG cells were cultured 
in Minimum Essential Medium Eagle (MEM) with 10% FBS, 1% penicillin/streptomycin, and 
1% essential amino acids under the same conditions. The JNK wild-type and knock-out mouse 
embryonic fibroblasts (MEF) (JNK wt, JNK1-/-, JNK2-/-, JNK1/2-/-) were provided by Dr. 
Zhimin Lu (M.D. Anderson Cancer Center, Houston, TX). The AMPKα1 wild-type and knock-
out MEF cells were obtained from Keith Laderoute (SRI International, San Francisco, CA). 
MEF cells were cultured in DMEM/F-12 50:50 medium with 10% FBS at 37°C in 5% CO2 in 
air.  
 
Reagents. The JNK kinase inhibitor SP600125, anisomycin, paclitaxol and bafilomycin A1 
were purchased from Sigma-Aldrich. Rapamycin was purchased from Calbiochem. 
Recombinant human protein interferon-γ (IFNγ) was purchased from Prospec (East Brunswick, 
NJ). Antibodies to phospho-AKT (S473), AKT, AMPKα1, TSC2, LC3, phospho-JNK 
(T183/Y185, T221/Y223), phospho-c-Jun (S63), c-Jun, beclin 1 were purchased from Cell 
Signaling Technologies. Anti-phospho-Bcl-2 and anti-JNK2 were purchased from Abcam. 
Anti-JNK1, anti-JNK3, anti-panJNK, anti-E1A, anti-p62, anti-actin, and anti-Bcl-2 antibodies 
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were purchased from Santa Cruz Biotechnology. Anti-adenoviral hexon was purchased from 
Novus Biologicals, and anti-adenoviral fiber from ThermoScientific. Allophycocyanin (APC)-
conjugated anti-mouse secondary antibodies and fluorescein isothiocyanate (FITC)-conjugated 
secondary antibody were purchased from Santa Cruz Biotechnology. 
 
Adenoviral production and infection. The Delta-24-RGD (∆24RGD) and wild-type adenovirus 
were produced previously by our laboratory in collaboration with Roman Alemany (Barcelona, 
Spain) (Fueyo et al., 2000; Fueyo et al., 2003). Briefly, the ∆24RGD adenovirus was 
constructed from a modified adenovirus type 5 genome (Microbix Biosystem Inc., Ontario, 
Canada) as follows. The backbone plasmid pXCl encompasses the adenovirus type 5 genome 
from nucleotides 22-5790. Using phosphorylated mutagenic primers, 24 bases from 919-943 
were looped out and deleted, corresponding to amino acid residues L, T, C, H, E, A, C, and F 
of the E1A  protein sequence. The E1 fragment containing the 24-bp deletion was isolated from 
the plasmid pXC1-∆24 and cloned by homologous recombination into the ClaI–digested 
plasmid pVK503 containing the RGD-4C sequence inserted into the HI loop of adenoviral fiber 
(Pasqualini et al., 1997). The full genome of the new virus was released from the plasmid 
backbone by digestion with PacI, and the linear viral DNA was transfected into HEK 293 cells 
to rescue the ∆24RGD adenovirus. The Delta-24-FvIII (∆24FvIII) was constructed through 
inserting the EGFRvIII epitope (LEEKKGNYVVT) into the HI loop of fiber protein between 
amino acid 533 and 534 (Krause et al., 2006). First the sequence coding for the EGFRvIII 
epitope was incorporated into the fiber gene in vector pXK-F containing XbaI–KpnI fragment 
of pVK500C (Mahasreshti et al., 2006) through site-directed mutagenesis. Next, the Xba I-Kpn 
I fragment from the resulting vector pXK-FvIII was co-tranduced with SwaI-linearized 
pVK500C.delta-24 into E. coli BJ5183 to allow for homologuos recombination (Piao et al., 
 - 20 - 
 
2009).  The plasmids were transfected into HEK293 cells in order to rescue the virus which 
was then propagated in A549 cells. Cells were seeded 24h prior to adenoviral infection. They 
were infected with adenoviruses at cell line-specific multiplicities of infection (MOI) for 
specified time-points. Floating and attached cells were collected for respective experiments as 
described below.  
 
Human Phospho-kinase Antibody Array kit. The Human Phospho-kinase Antibody Array Kit 
was purchased from RandD systems. The array was performed according to the manufacturer’s 
protocol. Briefly, MRC5 human lung fibroblasts were infected with wild-type adenovirus for 
16, 32, and 48 h. Uninfected cells (0h) were used as a control. The cells were collected and 
lysed using Lysis Buffer 6 from the kit, and the concentration of protein determined by the 
Bradford Protein Assay (Bio-Rad). After blocking the nitrocellulose membranes bound with 
phospho-specific antibodies to each kinase in duplicate, they were incubated with 400 µg of 
protein overnight at 4oC. The membranes were washed and incubated with Detection Antibody 
Cocktails of biotinylated antibodies specific for the phosphorylated kinases. HRP-conjugated 
Streptavidin antibodies and chemiluminescent detection reagents were used to visualize the 
amount of protein.  
 
SDS-PAGE and western blot analysis. Cells were lysed with RIPA lysis buffer [150 mM 
NaCl, 50 mM Tris-HCl pH 7.5, 0.1% sodium dodecyl sulfate (SDS), 0.5% sodium 
deoxycholate, 1% NP-40, protease inhibitor cocktail (Sigma), phosphatase inhibitor cocktail 
(Millipore)]. Protein concentrations were determined using a Bradford Protein Assay (Bio-
Rad).  Protein samples (25 µg) in 1X SDS loading buffer were boiled and loaded into tris-
glycine SDS-PAGE gels (Invitrogen). Samples were separated via electrophoresis at a constant 
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voltage of 100v (~2 1/2 hr) in 1X Tris-glycine running buffer.  Gels were then transferred to 
polyvinylidine fluoride membrane via western blotting (25v for 40 min in a Bio-Rad semi-dry 
transfer apparatus).  The membranes were blocked using 5% non-fat milk in 1X TBS-T (0.05% 
Tween) for 1 h at room temperature and then incubated overnight at 4°C in a primary antibody 
at appropriate dilutions as follows: phospho-AKT (S473; 1:1000), AKT (1:1000), AMPKα1 
(1:1000), TSC2 (1:500), LC3 (1:1000), phospho-JNK (T183/Y185, T221/Y223; 1:1000), 
phospho-c-Jun (S63; 1:1000), c-Jun (1:1000), beclin 1 (1:500), ahospho-Bcl-2 (S87; 1:1000), 
JNK1 (1:5000), JNK2 (1:1000), JNK3 (1:500), panJNK (1:1000), E1A (1:5000), p62 (1:1000), 
actin (1:5000), and Bcl-2 (1:500). Membranes were washed three times with TBS-T (0.05% 
Tween) and then incubated at room temperature for 1 h with appropriate secondary antibodies 
(ThermoScientific; 1:4000) prepared in 1% non-fat milk in TBS-T.  SuperSignal West Femto 
(ThermoScientific) and HyBlot CL autoradiography film (Denville Scientific Inc.) were used to 
visualize protein bands. 
 
DNA vectors and transfection. The pEGFP-LC3 plasmid used to detect GFP-LC3 puncta was 
purchased from Addgene. The plasmid was amplified in DH5α MAX Efficiency competent 
cells (Invitrogen). Individual clones were selected in Luria broth and 100 µg/ml kanamycin 
(Sigma-Aldrich).  The vector was isolated and purified (Miniprep, Qiagen) from each colony. 
U87 MG cells were seeded 24 h prior to transfection to about 60-70% confluency. X-
tremeGENE HP DNA transfection reagent (Roche) was used to transfect vectors into cells.  In 
200 µl of serum-free media, 2 µg of plasmid was combined with 10 µl of transfection reagent 
and allowed to incubate at room temperature for 20 min. The mixture was added drop-wise to 1 
ml of culture media in a 6-well plate and incubated with the cells for 48 h prior to treatment. 
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RNA interference. For short-hairpin RNA transfection of TSC2, the shTSC2 plasmid was 
purchased from OriGene. FuGENE 6 DNA transfection reagent (Roche) was used to introduce 
the plasmid into U251 cells. In 200 µl of serum free media, 2 µg of shRNA plasmid was 
incubated with 6 µl of transfection reagent at room temperature for 15 min. The mixture was 
added to cells for 48 h. A stable cell line was established through puromycin selection (0.5 
µg/ml). U87 MG cells were seeded into 6-well plates 24 h prior to small-interfering RNA 
(siRNA) transfection.  INTERFERin (Polyplus Transfection, Illkirch, France) was employed to 
transfect the siRNAs against JNK1 and JNK2 into cells according to the manufacturer’s 
protocol.  Briefly, 50nM siRNA oligonucleotides were combined with 10µl of transfection 
reagent in 200 µl serum free media and added to cells after 15 min of incubation at room 
temperature. SiRNA oligonucleotides for JNK1 (M-003514-04-0005) and JNK2 (M-003505-
02-0005) were purchased from Dharmacon (ThermoScientific).  
 
Co-immunoprecipitation. Cells were infected with AdWT or ∆24RGD for up to 48 h. Floating 
and attached cells were collected and lysed with immunoprecipitation (IP) lysis buffer (100 
mM NaCl, 50 mM Tris-HCl pH 7.4, 2 mM EDTA, 10% glycerol, 1% IgePal CA-630). The cell 
samples were pre-cleared with Protein A/G (1:1) agarose beads for 2 h. An anti-Bcl-2 antibody 
(1:100) or anti-p62 antibody (1:100) was added to lysates to rotate at 4oC overnight. Complexes 
of proteins were immobilized with Protein A/G (1:1) agarose beads. Immunoprecipitated 
samples, pre-cleared beads, and 5% input were analyzed via western blotting. Antibodies to 
beclin 1 (1:1000), adenoviral hexon (1:10,000), and adenoviral fiber (1:1000) were used to 
detect their interaction with Bcl-2 or p62. Clean-Blot IP Detection Reagent HRP 
(ThermoScientific) was used to visualize proteins bound by all anti-rabbit primary IgGs, 
reducing the detection of heavy and light chains.  
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Animal protocol. All animal studies were performed in the Department of Veterinary Medicine 
at The University of Texas MD Anderson Cancer Center in accordance with institutional 
guidelines and ethical guidelines for experimental animal care and approved by the MD 
Anderson IACUC. U87 human glioma cells (5 x 105) were engrafted into the caudate nuclei of 
athymic mice using a guide-crew system. In brief, a 2.6-mm guide screw with a 0.5-mm 
diameter central hole is implanted into a drill hole made 2.5 mm lateral and 1 mm anterior to 
the bregma. It is capped with a stylet between treatments. Tumor cells or therapeutic agents are 
injected using the 26-gauge needle of a Hamilton syringe with a cuff to determine the depth of 
injection. The procedure has been described and validated previously (Lal et al., 2000). Three 
days after cell implantation, the animals were given 5 µl intratumoral injections of ∆24RGD 
(106 pfu/ml) or PBS. Animals exhibiting generalized or local signs of disease were euthanized 
using a CO2 chamber (~28-35 days after cell implantation). Their brains were then removed, 
fixed in 4% formalin for 48 h, and embedded in paraffin, and 5µm slices of them were mounted 
on slides.  
 
Tissue immunofluorescence  
Slides were baked for 45 minutes at 60°C followed by deparaffinization in xylene and 
rehydration in serial dilutions of ethanol employing the following procedure: 2X5 min in 100% 
ethanol; 2X5 min in 95% ethanol; 5 min in 70% ethanol; 3X5 min in PBS + 0.05% Tween-20. 
Hematoxylin- and eosin-stained coronal sections were evaluated for evidence of tumors. Heat-
mediated antigen retrieval was performed on the tissue using 10 mM citrate buffered to pH 6.0 
and a pressure cooker for 20 min followed by 20 min at room temperature to cool. The tissues 
were blocked using appropriate serum and a streptavidin/biotin blocking kit (Vector Labs). 
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Anti-phospho-JNK (T183/Y185, T221/Y223; Cell Signaling; 1:100) or anti-phospho-Bcl2 
(S87; Abcam; 1:100) and anti-hexon (ThermoScientific; 1:500) primary antibodies were 
applied overnight at 4°C followed by incubation with their respective biotin-conjugated 
secondary antibodies (Vector Labs; 1:100). Dylight 594- or Dylight 488-conjugated 
streptavidin (Vector Labs; 1:100) were used to visualize the co-localization of infected cells 
(i.e., hexon) and p-JNK or p-Bcl-2. Vectashield Mounting Media with DAPI (Vector Labs) was 
used to stain nuclei and seal slides. Images were captured on a Zeiss Axiovert Zoom 
fluorescence microscope (Carl Zeiss, Inc.) equipped with AxioCam MRM camera and 40x 1.3 
oil EC Plam-NEOFLUAR objective, using Immersol (n = 1.518) at room temperature. The 
acquisition software utilized was AxioVision Release 4.7.1 (Carl Zeiss, Inc).  
 
Electron microscopy. Cells (>1,000,000) were fixed in a solution that comprised 3% 
glutaraldehyde plus 2% paraformaldehyde in 0.1 M cacodylate buffer (pH 7.3). The samples 
were treated with 0.1% cacodylate-buffered tannic acid and then fixed for an additional 1 hour 
with 1% buffered osmium tetroxide. They were then stained with 1% uranyl acetate. All 
reagents were obtained from Sigma-Aldrich. The samples were dehydrated in ethanol at 
increasing concentrations, infiltrated, and then embedded in Spurr's low-viscosity medium. 
They were polymerized for 2 days at 70°C. Ultrathin sections were cut in a Leica 
Ultracutmicrotome, stained with uranyl acetate and lead citrate in a Leica EM stainer, and 
visualized using a JEM-1010 transmission electron microscope (JEOL USA Inc.) at an 
accelerating voltage of 80 kV. Digital images were obtained using an imaging system from 
Advanced Microscopy Techniques. 
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Flow cytometry. Cells were treated for respective time-points, trypsinized and collected in PBS 
with 1% BSA. Interferon gamma (INFγ) was added to cells at 300 units/mL. Bafilomycin A1 
was used at indicated concentrations. Live cells were stained for adenoviral antigens using a 
combination of mouse anti-adenovirus (blend) coating (Millipore; 1:75) and mouse anti-
adenovirus fiber antibodies (1:75) for 30 min at 4°C. After washing, the cells were stained with 
allophycocyanin (APC)-conjugated anti-mouse secondary antibodies (1.75) for 30 min at 4°C. 
For detection of the EGFRvIII epitope (LEEKKGNYVVT), a monoclonal antibody termed 
L8A4 (1:25) was graciously provided by Dr. Amy Heimberger (MD Anderson Cancer Center, 
Houston, TX). After 30 min incubation at 4oC, the cells were stained with a fluorescein 
isothiocyanate (FITC)-conjugated secondary antibody. The live cells were analyzed using a BD 
FACSCalibur (Becton-Dickenson). Dead cells were excluded using propidium iodide or 
ethidium homodimer-1 staining prior to analysis. The data represent at least four independent 
experiments.  
 
Splenocyte isolation and activation. All animal studies were performed in the veterinary 
facilities at The University of Texas – M. D. Anderson Cancer Center in accordance with 
institutional guidelines and ethical guidelines for experimental animal care and approved by the 
MD Anderson IACUC. C57BL/6 mice were infected with 108 plaque forming units of 
∆24RGD adenovirus twice (Day 1 and 3) intracranially through the guide-screw method 
described above. The animals were euthanized using a CO2 chamber on Day 14 and the spleens 
were collected. The spleens were manually homogenized and passed through a 100 µm nylon 
cell strainer. The red bloods cells were removed using ACK Lysing Buffer (Lonza). In parallel, 
wild-type and JNK1/2 DKO (JNK1/2 -/-) MEF cells were seeded 1 x 105 in a 6-well plate (in 
triplicate). The cells were infected with 100 MOI of ∆24RGD for 24 h, trypsinized and re-
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plated into a 96-well plate at 5 x 104 cells per well in RPMI 1640 media with 10% FBS and 5 
µM beta-mercaptoethanol. The splenocytes (1 x 106 cells) from naïve and immunized mice 
were incubated with the pre-infected MEF cells in culture for 24 h. For experiments including 
blocking antibodies, the pre-infected MEF cells were incubated with 2µg of anti-mouse MHC 
Class I (H-2Kd; eBioscience), anti-mouse MHC Class II (I-A/I-E; eBioscience), or mouse IgG 
antibodies (Santa Cruz) 2 h prior to co-culture with primed splenocytes. The splenocytes were 
then incubated with the pre-infected MEF cells and blocking antibodies for 24 h. The Mouse 
IFNγ ELISA Kit (ThermoScientific) was used to evaluate the concentration of IFNγ in media 
extracted from the co-culture. The ELISA was performed according to the manufacturer’s 
instructions. In brief, 50 µl of co-culture media was incubated in a 96-well plate coated with 
antibodies to IFNγ. A biotinylated IFNγ detection antibody followed by HRP-conjugated 
streptavidin and chemiluminescent reagents revealed the concentration of IFNγ in each sample. 
The absorbance (450nm-550nm) was analyzed by an Omega Microplate Reader (BMG 
Labtech) and the concentration of IFNγ (pg/ml) was determined by comparing to the standard.  
 
Statistical analysis. The two-tailed Student t-test was used to determine the statistical 
significance of treated and infected samples relative to control samples. Only p values less than 
0.05 were accepted as statistically significant. 
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Chapter III: The archetypal signaling pathway for autophagy is not employed during 
adenovirus mediated autophagy. 
 
Rationale and Expectations: 
The archetypal signaling events that regulate the induction of autophagy have been 
investigated thoroughly (Figure 3). Many forms of cellular stress, including starvation, 
stimulate phosphorylation of adenosine monophosphate-activated protein kinases (AMPK) 
(reviewed by Hardie, 2004). AMPKs phosphorylate tuberous sclerosis protein 2 (TSC2), 
facilitating autophagy through inhibition of a pivotal negative regulator of autophagy, the 
mammalian target of rapamycin (mTOR) (Inoki et al., 2003; Kim et al., 2011). Mammalian 
TOR is a well-established inhibitor of autophagy (Noda and Ohsumi, 1998). Phosphorylation of 
mTOR through AKT signaling results in inhibition of autophagy (Inoki et al., 2002). The AKT 
pathway is activated by growth factors and nutrients; thus, signaling to the cell that recycling of 
cellular components through autophagy is not necessary, and energy should be directed toward 
transcription and cell proliferation through activation of mTOR and the downstream substrate 
p70S6K (Jefferies et al., 1997; Inoki et al., 2002). AMPK and AKT function inversely to 
activate or inhibit autophagy, respectively, through TSC2. As such, AKT inactivates TSC2, 
permitting mTOR to inhibit autophagy (Inoki et al., 2002). Therefore, upon investigating 
adenovirus-mediated autophagy, we initially expected to observe similar variations in the 
phosphorylation of key components of this canonical signaling pathway. 
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Results: 
 
AKT and mTOR, but not AMPK, are phosphorylated in adenovirus-infected cells. Our 
investigation began by utilizing a high-throughput antibody array to evaluate the 
phosphorylation status of numerous kinases during adenovirus infection. We infected MRC5 
immortalized, healthy lung fibroblasts with wild-type adenovirus (AdWT) for increasing time-
points and surveyed the cellular protein content using a Human Phospho-kinase Antibody 
Array (RandD Systems). The array revealed a multitude of kinases that exhibited changes in 
phosphorylation status in response to adenovirus infection (Figure 5, Table 1). Several key 
modulators of the archetypal pathway to autophagy initiation were included in the array. 
Unexpectedly, we observed that there was minor changes in the phosphorylation of two AMPK 
isoforms (AMPKα1 and AMPKα2), whose activation by phosphorylation elicits autophagy 
(Kim et al., 2011). Moreover and in agreement with this data, both AKT and mTOR were 
highly phosphorylated after adenovirus infection (Figure 6). We detected a 22-fold increase in 
phosphorylated AKT as early as 16h after infection that was maintained up to 48h. The 
phosphorylation of mTOR exhibited a time-dependent increase, peaking at a 31-fold phospho-
protein level 48h after infection (Figure 6). We also observed a 35-fold increase in p70S6K, 
which is a confirmed substrate of mTOR (Jefferies et al., 1997). In addition, we validated the 
phosphorylation of AKT in U87 malignant glioma (U87 MG) cells infected with the tropism-
enhanced ∆24RGD adenovirus. Infected cells exhibited an 11-fold increase in phospho-AKT 
levels that corresponded in time with LC3-I to LC3-II conversion, the marker of autophagy 
(Figure 7). Our data reveals the highest levels of AKT and mTOR phosphorylation were 
observed at 48 h (Figure 6-7); the last time-point examined and a time-point when autophagy is 
active (Figure 7). 
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Figure 5. A high-throughput profile reveals numerous phosphorylated kinases during 
adenovirus infection. The Human Phospho-kinase Antibody Array (R&D Systems) was 
employed to examine the phosphorylation status of a variety of kinases during infection of 
immortalized MCR5 healthy lung fibroblasts with wild-type adenovirus (AdWT). Cells were 
infected at an MOI of 50 for the indicated time-points and whole-cell protein lysates were 
analyzed by the array. The spots indicate phospho-protein levels and controls in duplicate. 
Please see table 1 for list of kinases. 
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Table 1. A list of kinases detected by the Human Phospho-kinase Antibody Array and 
their corresponding phosphorylation site(s). The table includes the phosphorylation site(s) 
that was detected by the array as well as the coordinates where the kinase can be found within 
the array. Kinases highlighted in orange are components of the canonical AMPK/Akt/mTOR 
pathway of autophagy, while kinases highlighted in blue are of the MAP kinase signaling 
cascade. 
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Figure 6. The phosphorylation status of proteins during adenovirus infection contradicts 
the archetypal autophagy pathway. A, The expression levels of phosphorylated protein for 
AMPKα1 (T174), AMPKα2 (T172), Akt (S473), mTOR (S2448), and p70S6K (T421/S424) 
were evaluated in immortalized MCR5 healthy lung fibroblasts during adenovirus infection. 
Cells were infected with wild-type adenovirus (AdWT) at an MOI of 50 for the indicated time-
points, and whole-cell protein lysates were analyzed using the Human Phospho-kinase 
Antibody Array. The spots indicate phospho-protein levels in duplicate. B, Densitometry was 
performed on each spot and then graphed as an average of the two. Fold-change in phospho-
protein levels were generated relative to uninfected cells (0h). 
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Figure 7. ∆24RGD infection stimulates AKT phosphorylation in malignant glioma cells 
undergoing autophagy. U87 MG cells were infected with UV-inactivated and active ∆24RGD 
adenovirus at an MOI of 50 for indicated time-points. AKT phosphorylation was examined 
with an anti-phospho-AKT (p-AKT) antibody. Relative fold-change of p-AKT was determined 
by densitometry analysis. 
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AMPK and TSC2 are not required for adenovirus-induced autophagy. In order to verify that 
AMPK phosphorylation does not contribute to adenovirus-mediated autophagy, we infected 
AMPKα1 wild-type (AMPK wt) and knock-out (AMPK -/-) mouse embryonic fibroblasts 
(MEF cells) with AdWT for 48 h. Consistent with the results we obtained from the array, 
adenovirus infection in AMPK wt and AMPK -/- MEF cells induced an equivalent degree of 
autophagy.  Conversion of LC3-I to the lipidated and membrane-bound LC3-II was observed 
48h after infection in both cell lines, irrespective of AMPKα1 expression (Figure 8A). This 
data indicates AMPKα1 expression is not required for autophagy in adenovirus infected cells. 
During starvation-induced autophagy, AMPKs initiate autophagy through phosphorylation of 
TSC2 (Inoki et al., 2003; Inoki et al., 2002).Therefore we utilized RNAi technology to knock-
down TSC2 in U251 glioma cells followed by infection with AdWT adenovirus for 48h 
(Figure 8B). Again using LC3-I to LC3-II conversion as a marker, autophagy was observed 
48h after infection in all cell lines, regardless of TSC2 expression status (Figure 8C). Thus, in 
our system, the archetypal pathway that triggers starvation-induced autophagy was likely not 
responsible for the dramatic induction of autophagy observed in adenovirus-infected cells.  
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Figure 8. Adenovirus-mediated autophagy does not require expression of AMPKα1 or 
TSC2. A, AMPKα1 wild-type and knock-out MEFs were treated with UV-inactivated or active 
AdWT at an MOI of 100 for 48 h. Cell lysates were analyzed by western blot for conversion of 
LC3-I to LC3-II, a marker of autophagy. B, TSC2 expression was inhibited by short-hairpin 
RNA oligonucleotides in U251 glioma cells for 48h. C, Parental cells and cells transfected with 
non-coding or TSC2 short hairpin RNAs were infected with ∆24RGD at an MOI of 10 for 48 h. 
Western blot analysis was performed to detect LC3 conversion. 
 - 35 - 
 
Conclusions: 
 
Divergent from starvation- and stress-induced autophagy, adenovirus-induced 
autophagy does not require the activation of AMPKs or TSC2. Conversely, adenovirus 
infection triggers the phosphorylation of inhibitory components of the autophagy signaling 
pathway, AKT, mTOR and p70S6K. Our counterintuitive results were in contradiction with the 
accepted tenet of molecular events that characterizes starvation-related autophagy (Noda and 
Ohsumi, 1998; Inoki et al., 2002; Inoki et al., 2003; Kim et al., 2011), and immediately 
suggested that adenoviruses utilize an alternative pathway in order to initiate autophagy that is 
able to surmount the autophagy inhibitory effects of an activated AKT/mTOR pathway. 
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Chapter IV: C-Jun N-terminal kinases are activated during adenovirus infection.  
 
Rationale and Expectations: 
JNK is a mitogen-activated kinase (MAPK) involved in numerous cellular processes, 
including autophagy. Recent studies on starvation- and ceramide-induced autophagy 
demonstrated that one isoform of the c-Jun N-terminal kinase (JNK) family, JNK1, positively 
regulates autophagy (Wei et al., 2008; Pattingre et al., 2009). In addition, JNK kinases may 
play a role in the regulation of ER stress-induced autophagy and oxidative stress-induced 
autophagy (Ogata et al., 2006; Wong et al., 2010), as well as in the shift from autophagy to 
autophagic cell death (Shimizu et al., 2010).  
Importantly, there is evidence regarding JNK activation during adenovirus infection. 
JNK is activated by the interaction of adenoviral fiber with the coxsackie adenovirus receptor 
during adenoviral attachment to respiratory cells (Tamanini et al., 2003; Tamanini et al., 2006). 
Moreover, JNK is an important effector of the anti-adenoviral immune response. Upon 
replication of adenoviral DNA and transcription of adenoviral RNAs, cellular receptors (e.g., 
TLR9) and proteins (e.g., Rig-1) recognize the foreign oligonucleotides and stimulate JNK 
signaling for expression of pro-inflammatory cytokines (Ichijo H., 1999; Johnson and Lapadat, 
2002; Barton and Medzhitov, 2003; Minamitani et al., 2011). Furthermore, adenovirus-infected 
cells characteristically express and release type 1 interferons at high levels via JNK-dependent 
and independent pathways (Basner-Tschakarjan et al., 2006; Minamitani et al., 2011). 
Interferons are also potent activators of JNK signal transduction leading to apoptosis (Ichijo et 
al., 1997; Caraglia et al., 1999; Sung et al, 2001; Takada et al., 2005). The canonical 
interleukin response to adenovirus also includes tumor necrosis factor-alpha, which can activate 
JNK through Ask-1 signaling (Sung et al., 2001; Nishitoh et al., 1998; Yoon et al., 2008). In 
addition to the possible cellular response to adenoviral infection, adenoviral proteins may 
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directly interact with MAPK kinases (MAPKK) 5 or 7 to trigger JNK phosphorylation (See and 
Shi, 1998). Therefore, JNK activation in adenovirus-infected cells may result from a multi-
mechanistic process involving redundant activators from the cellular and viral repertoire.  
Although a role for JNK in adenovirus-induced autophagy was not previously reported, 
we hypothesized JNKs would be the critical component of a complex network that regulates 
autophagy during adenovirus infection. Importantly, we expected JNK activation to occur not 
only in adenovirus-infected healthy cells as previously described, but also in cancer cells 
infected with the oncolytic, tropism-enhanced ∆24RGD adenovirus. 
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Results: 
 
JNK and c-Jun are phosphorylated during adenoviral infection. The Human Phospho-Kinase 
Antibody Array (RandD Systems) encompassed many mitogen activated kinases (MAPK), 
including those of the JNK pathway. We assessed the levels of phosphorylated JNK and the 
downstream transcription factor c-Jun. Phosphorylation of both JNK and c-Jun increased 
during adenoviral infection (Figure 9A,B). As early as 16h after infection, there was a ~3.5-fold 
increase in the levels of phosphorylated JNK. In agreement with JNK activation, its 
downstream target, c-Jun, maintained a ~4.5-fold increase when compared to the basal levels 
observed in mock-infected cells (Figure 9B). However, JNK was phosphorylated in a time-
dependent manner, and peaked at a 35-fold increase in phospho-JNK levels 48 h after 
adenoviral infection (Figure 9A). ERK1/2 are MAPK that often cross-talk with JNK signaling 
(Johnson and Lapadat, 2002). Interestingly, modifications in the phosphorylation of ERK1 and 
ERK2 were not evident at any point after adenoviral infection, thereby suggesting some degree 
of specificity in the adenovirus-mediated activation of MAPKs (Figure 9B).   
 
JNK pathway components are phosphorylated in adenovirus-infected cancer cells. We 
confirmed the data obtained from the antibody array via western blot analyses of JNK and c-
Jun phosphorylation in U87 malignant glioma (MG) cells (Figure 10A), A549 lung carcinoma 
cells (Figure 10B), and HeLa cervical carcinoma cells (Figure 10C) infected with wild-type 
adenovirus (AdWT) and/or ∆24RGD. In U87 MG cells, we detected phosphorylation of JNK 
and the downstream transcription factor c-Jun 24 h after adenoviral infection. The levels were 
comparable to those detected in cells treated with anisomycin, a chemical activator of JNK 
phosphorylation (Kyriakis et al., 1994). As expected, the tropism enhanced ∆24RGD 
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Figure 9. Adenovirus infection induces phosphorylation of c-Jun N-terminal kinases 
(JNK) and their substrate, c-Jun. A, Phosphorylated protein levels of JNK (T183/Y185, 
T221/Y223), ERK1/2 (T202/Y204, T185/Y187) and B, c-Jun (S63) were measured in whole-
cell protein lysates from AdWT-infected MCR5 cells using the Human Phospho-Kinase 
Antibody Array. Cells were infected with an MOI of 50 for indicated time-points. Fold-increase 
in phosphorylated protein levels was determined by densitometry analysis of the antibody 
array. Values are an average of the spots in duplicate displayed on the bottom. 
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Figure 10. Wild-type and ∆24RGD adenovirus replication activates the JNK signaling 
pathway in host cells. A, U87 MG cells were infected with UV-inactivated (UVi) or active 
AdWT or ∆24RGD at an MOI of 50. B, A549 lung carcinoma cells were infected with UVi or 
active AdWT at an MOI of 25. C, HeLa cervical carcinoma cells were infected with UVi or 
active AdWT or ∆24RGD at an MOI of 25. Western blotting was performed on whole-cell 
lysates for detection of phosphorylated JNK pathway proteins. Anisomycin (5 µM, 30 min) was 
used as a positive control for JNK pathway activation. 
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adenovirus (Fueyo et al., 2000; Fueyo et al., 2003) induced phosphorylation of JNK and c-Jun 
to a greater degree than did AdWT at corresponding doses (Figure 10A).  Similar results were 
obtained with A549 lung carcinoma cells (Figure 10C). A time-course experiment in HeLa 
cells confirmed that JNK was phosphorylated as early as 6 h after infection with AdWT or 
∆24RGD. JNK phosphorylation increased drastically over time without exhibiting changes in 
the level of total JNK protein expression (Figure 10B). Phosphorylated c-Jun was also detected 
6h after adenoviral infection and increased over time. Phosphorylation of JNK pathway 
components occurred concurrently with expression of the adenoviral protein E1A (Figure 
10B,C). Importantly, UV-inactivated adenoviruses that are replication-incompetent did not 
trigger JNK or c-Jun phosphorylation. Taken together, these data indicate that the JNK 
signaling pathway is activated during adenoviral infection.  
 
Infected glioma cells exhibit JNK phosphorylation in vivo. In order to corroborate the in vitro 
data and determine the physiological relevance of our data, we sought to ascertain whether 
adenoviral infection is followed by JNK phosphorylation in human glioma xenografts infected 
with ∆24RGD. To this end, we examined the brains of U87 glioma-bearing nude mice injected 
intratumorally with 107 plaque-forming units of ∆24RGD. JNK phosphorylation was detected 
in the tumors infected with ∆24RGD (Figure 11, middle panels). Immunofluorescent 
examination of viral and phospho-JNK proteins under a deconvolution microscope revealed the 
co-localization of phospho-JNK (green fluorescence) with the adenoviral coat protein hexon 
(red fluorescence). Importantly, we observed the nuclear localization of JNK during adenoviral 
infection, which is required for JNK-mediated activation of transcription factors, including c-
Jun (Kyriakis et al., 1994). As expected, neither phospho-JNK nor adenoviral hexon could be 
detected in the adjacent healthy brain tissue (Figure 11, bottom panels); the recombinant  
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Figure 11. Human glioma xenografts infected with ∆24RGD exhibit JNK 
phosphorylation. U87 MG cells (105) were implanted intracranially in nude mice, and infected 
intratumorally with 10
7
 plaque forming units (pfu) ∆24RGD. Brain sections were imbedded in 
paraffin and mounted on slides. Antibodies for phospho-JNK (green fluorescence) and hexon 
(red fluorescence) were used to detect infected cells undergoing JNK activation. DAPI (blue 
fluorescence) was used as a nuclear stain. Deconvolution microscopy was employed to 
visualize brain tissue from 4 mice per treatment. The experiment was repeated twice with 
mounted tissue sections from each animal. Representative images of the central tumor from 
mice mock infected with PBS (top panel) or infected with ∆24RGD (middle panel) are 
depicted. Images of the uninfected healthy brain tissue (bottom panel) surrounding the 
∆24RGD-infected tumor cells are also included. 
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∆24RGD adenovirus cannot replicate in healthy cells with an intact Rb pathway (Fueyo et al., 
2000; Fueyo et al., 2003). Phospho-JNK was also not detected in tumor or normal brain tissues 
of mice treated with PBS vehicle alone (Figure 11, top panels).  
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Conclusions: 
JNK and the downstream constituent c-Jun were phosphorylated in adenovirus-infected 
cells. JNK activation appeared to be ubiquitous; we demonstrated that immortalized, healthy 
fibroblasts, malignant gliomas, cervical carcinoma cells, and lung carcinoma cells exhibited 
JNK phosphorylation during adenovirus infection with either the wild-type adenovirus or the 
genetically-modified, oncolytic ∆24RGD adenovirus. We established that JNK phosphorylation 
occurred in ∆24RGD-infected glioma xenografts, indicating our data was not a product of the 
in vitro culture conditions. Importantly, our data revealed in vitro and in vivo that JNK pathway 
activation is replication-dependent suggesting interactions between adenoviral coat proteins 
and cellular receptors during internalization is likely not the cause.  
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Chapter V. JNK regulates Bcl-2 phosphorylation during adenovirus-mediated autophagy. 
 
Rational and Expectations:  
Bcl-2 is a negative regulator of autophagy due to its mitigating interaction with beclin 1, 
which attenuates the formation of beclin1 complexes in the isolation membrane during 
autophagy initiation (Figure 3) (Kihara et al., 2001; Pattingre et al., 2005; Levine et al., 2008). 
Importantly, under starvation conditions JNK1-dependent phosphorylation of Bcl-2 suffices to 
dissociate Bcl-2/beclin 1 heterodimers and thus allows autophagy to proceed (Wei et al., 2008). 
Ceramide treatment also follows this same paradigm (Pattingre et al., 2009). Additionally, 
evidence shows artificial activation of RNase L by 2'-5' linked oligoadenylates formed during 
viral double stranded RNA recognition induces JNK-dependent Bcl-2 phosphorylation 
(Siddiqui et al., 2012).  
There is no previous study on the phosphorylation status of mammalian Bcl-2 in cells 
infected with adenovirus. The nature of JNK-mediated phosphorylation of Bcl-2 remains under 
investigation and has not yet been specifically addressed in adenovirus-induced autophagy; 
however, we expect that the JNK activation we observed during adenovirus infection would 
result in Bcl-2 phosphorylation that would coincide with the release of beclin 1 and activation 
of autophagy. 
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Results: 
 
Bcl-2 is phosphorylated in adenovirus-infected cells undergoing autophagy. In order to 
ascertain the role of JNK and Bcl-2 during adenovirus-mediated autophagy, we first needed to 
assess Bcl-2 phosphorylation in adenovirus-infected cells. Using western blotting techniques, 
we detected Bcl-2 phosphorylation as early as 24h after infection with AdWT or ∆24RGD 
adenovirus in U87 MG (Figure 12A), HeLa cervical carcinoma, (Figure 12B) as well as A549 
lung carcinoma cells modified to stably over-express mammalian Bcl-2 (a generous gift of Tim 
McDonnell, M.D. Anderson Cancer Center) (Figure 12C). Phosphorylation of Bcl-2 increased 
consistently and reproducibly in all three cell lines 48 h after infection (Figure 12A-C). In U87 
cells, phospho-Bcl-2 levels reached a 20-fold increase 48 h after adenoviral infection (Figure 
12A), comparable to the positive control Paclitaxol. Relevant to our hypothesis, we observed 
JNK and Bcl-2 phosphorylation were events parallel to the induction and development of 
autophagy. Thus, western blot analyses revealed a remarkable conversion of LC3-I to lipidated, 
membrane bound LC3-II after adenoviral infection in all cancer cell lines examined (Figure 
12A-C). These data strongly indicated that JNK pathway activation and Bcl-2 phosphorylation 
coincide with the formation of autophagosomes (Kabeya et al., 2000).  
 
Glioma xenografts infected with ∆24RGD express phosphorylated Bcl-2. Next, we assessed 
physiological relevance of this phenomenon in human glioma xenografts treated with ∆24RGD 
adenovirus (Figure 13). Analogous to JNK, Bcl-2 was also phosphorylated (red fluorescence) 
in cells that concomitantly expressed the adenoviral coat protein hexon (green fluorescence). 
Unlike phospho-JNK, which is found in both the nucleus and cytoplasm of infected cells, 
phosphorylated Bcl-2 was localized to the cytoplasm as expected (Figure 13). Furthermore, 
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Figure 12. Wild-type and ∆24RGD adenovirus infection induces B-cell lymphoma 2 (Bcl-
2) phosphorylation. A, U87 MG cells were infected with UVi or active ∆24RGD adenovirus at 
an MOI of 50 and protein lysates were analyzed via western blot. B, HeLa cells were infected 
with UVi or active AdWT adenovirus at an MOI of 25. Cell lysates were prepared in IP lysis 
buffer, and incubated with antibodies to Bcl-2. Immunoprecipitated complexes and input (5%) 
samples were analyzed by western blot. C, A549 cells were stably transfected to express 
increased levels of Bcl-2. Cells were then infected with UVi or active AdWT adenovirus at an 
MOI of 25 and protein lysates examined by western blot. 
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Figure 13. Malignant gliomas infected with ∆24RGD exhibit Bcl-2 phosphorylation. U87 
MG cells (105) were implanted intracranially in nude mice, and infected intratumorally with 107 
pfu ∆24RGD. Brain sections were imbedded in paraffin and mounted on slides. Antibodies for 
phospho-Bcl-2 (red fluorescence) and hexon (green fluorescence) were used to detect infected 
cells undergoing JNK activation. DAPI (blue fluorescence) was used as a nuclear stain. 
Deconvolution microscopy was employed to visualize brain tissue from 4 mice per treatment. 
The experiment was repeated twice with mounted tissue sections from each animal. 
Representative images of the central tumor from mice mock infected with PBS (top panel) or 
infected with ∆24RGD (middle panel) are depicted. Images of the uninfected healthy brain 
tissue (bottom panel) surrounding the ∆24RGD-infected tumor cells are also included. 
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meticulous examination of the tumor and adjacent brain tissue of the ∆24RGD-infected, 
glioma-bearing mice revealed that Bcl-2 was phosphorylated in infected tumors but not in the 
normal brain tissue (Figure 13). As expected, neither tumor nor normal brain tissues obtained 
from mice treated with the PBS vehicle alone exhibited Bcl-2 phosphorylation. These in vivo 
results not only buttressed the validity and reproducibility of the in vitro observations by 
confirming and expanding our results, but also unequivocally demonstrated that JNK and Bcl-2 
phosphorylation in adenovirus-infected cells was not an artifact of the in vitro culture 
conditions.  
 
Adenovirus-induced Bcl-2 phosphorylation is JNK-dependent. Previous studies (Wei et al., 
2008; Pattingre et al., 2009; Siddiqui et al., 2012) and our data suggested a functional 
regulation of Bcl-2 by JNK. We used isogenic MEF cells to determine the extent to which JNK 
expression is required for Bcl-2 phosphorylation. We obtained MEF cells that were wild-type 
for JNK (JNK wt) and MEF cells lacking both JNK1 and JNK2 genes (JNK1/2 -/-). Of note, 
JNK3 is expressed at low levels in JNK wt and JNK1/2 -/- cell lines (Figure 15). In agreement 
with our previous observations, Bcl-2 phosphorylation increased dramatically in wild-type 
MEF cells infected with AdWT (Figure 14A). Conversely, infection of JNK1/2 -/- MEF cells 
did not induce an increase in Bcl-2 phosphorylation (Figure 14A). To determine the effect of 
JNK activation on Bcl-2 phosphorylation, we used a chemical inhibitor (SP600125) to prevent 
JNK phosphorylation in adenovirus-infected A549 lung carcinoma cells. Pre-treatment of cells 
with 25 µM SP600125 completely prevented Bcl-2 phosphorylation after infection with AdWT 
for 48 h (Figure 14B). Importantly, SP600125 inhibits the phosphorylation of all three JNK 
isoforms: JNK1, JNK2, and JNK3.  
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Figure 14. Adenovirus-induced Bcl-2 phosphorylation requires JNK expression and 
activation. A, Wild-type and JNK1/2 DKO (JNK1/2 -/-) MEFs were infected with UV-
inactivated or active AdWT adenovirus at an MOI of 100. Protein lysates were prepared in IP 
lysis buffer and incubated with antibodies to Bcl-2. Immunoprecipitated complexes and input 
(5%) samples were analyzed by western blot. B, A549 cells were stably transfected to express 
increased levels of Bcl-2, and treated with DMSO or SP600125 (25 µM) for 30 min prior to 
infection with AdWT at an MOI of 25 for 48 h. Whole-cell lysates were prepared and analyzed 
via western blot for Bcl-2 phosphorylation. Relative fold change in phospho-Bcl-2 was 
determined by densitometry analysis. 
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Figure 15. Several cell lines, including JNK1/2 DKO cells, express low levels of JNK3. 
Whole cell lysates from mouse brain, HeLa cells, U87 MG cells, and wild-type and JNK1/2 -/- 
MEF cells were analyzed by western blot for the expression of JNK3. 
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Knock-out of both JNK1 and JNK2 is required to inhibit Bcl-2/beclin 1 dissociation. We 
utilized additional isogenic MEF cells to determine the extent to which the isoforms JNK1 and 
JNK2 were required for eliciting the resultant dissociation of Bcl-2/beclin 1 protein complexes 
after Bcl-2 phosphorylation (Wei et al., 2008; Pattingre et al., 2009). We performed an 
immunoprecipitation assay to detect beclin 1 bound to Bcl-2. As expected, wild-type MEF cells 
exhibited a decrease in Bcl-2/beclin 1 complexes after infection with AdWT adenovirus 
(Figure 16). Importantly, we were also able to detect dissociation of beclin 1 from Bcl-2 in 
infected MEF cells lacking either JNK1 (JNK1 -/-) or JNK2 (JNK2 -/-). In contrast, adenoviral 
infection did not disrupt Bcl-2/beclin 1 heterodimers in JNK1/2 -/- MEF cells (Figure 16). To 
our knowledge, these data are the first demonstration that elimination of both JNK1 and JNK2 
is required to inhibit adenovirus-mediated Bcl-2 phosphorylation and subsequent modulation of 
beclin 1 interactions.  
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Figure 16. Knock-out of both JNK1 and JNK2 isoforms blocks the dissociation of Bcl-
2/beclin 1 complex and induction of autophagy by adenovirus.  Wild-type, JNK1 KO (JNK1 
-/-), JNK2 KO (JNK2 -/-), and JNK1/2 DKO (JNK1/2 -/-) MEFs were infected with AdWT 
adenovirus at an MOI of 100 for 48 h. Protein lysates were prepared in IP lysis buffer and 
incubated with antibodies to Bcl-2. Both Bcl-2-immunoprecipitated and input (5%) samples 
were analyzed via western blot for the interaction between beclin 1 and Bcl-2.  
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Conclusions: 
Our data clearly demonstrated JNK expression and activation regulates Bcl-2 
phosphorylation during adenovirus infection. Similar to JNK, Bcl-2 was also phosphorylated in 
infected tumors in vivo indicating that this pathway is functional in a whole system with 
potential interactions from the surrounding microenvironment. In addition, JNK-mediated Bcl-
2 phosphorylation triggered dissociation of Bcl-2/beclin 1 heterodimers. Contrary to the 
regulation involved in starvation-induced autophagy, knock-out of JNK1 alone was not able to 
inhibit Bcl-2 phosphorylation or release of beclin 1. Indeed, JNK1 and JNK2 isoforms may 
play redundant roles in Bcl-2-mediated regulation of beclin 1, because knock-out of both is 
.required to inhibit the event. JNK3 likely has a negligible effect upon this pathway; despite 
JNK3 being expressed in JNK1/2 double knock-out MEF cells, we were not able to detect an 
increase in Bcl-2 phosphorylation or Bcl-2/beclin 1 dissociation. Thus, we discovered an 
activated signaling pathway that has not been described previously in adenovirus-infected cells.  
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Chapter VI. JNK regulates adenovirus-mediated autophagy. 
 
Rational and Expectations:  
The regulation of autophagy through activation of JNK is well-documented. JNKs play 
a role in the regulation of ER stress-induced autophagy and oxidative stress-induced autophagy 
(Ogata et al., 2006; Wong et al., 2010), as well as in the shift from autophagy to autophagic 
cell death (Shimizu et al., 2010). The activation of JNK-dependent autophagy by cancer 
chemotherapeutic agents is under investigation as well. JNK expression and activation is 
required for autophagy induced by resveratrol, oridonin, and bufalin (Puissant et al., 2010; Cui 
et al., 2007; Xei et al., 2011). Interestingly, JNK has been implicated in regulating autophagy 
activated by insulin-like growth factor-1 and tumor necrosis factor-alpha signaling (Jia et al., 
2006).  Recent studies on starvation-induced autophagy demonstrated that one isoform of the c-
Jun N-terminal kinase (JNK) family, JNK1, positively regulates autophagy via phosphorylation 
of Bcl-2 in order to dissociate Bcl-2/beclin 1 heterodimers and thus allows autophagy to 
proceed (Wei et al., 2008). Ceramide treatment also follows this same paradigm (Pattingre et 
al., 2009). In addition, artificial activation of RNase L by 2'-5' linked oligoadenylates formed 
during viral double stranded RNA recognition has been shown to induce JNK-dependent Bcl-2 
phosphorylation, Bcl-2/beclin 1 dissociation, and autophagy induction (Siddiqui et al., 2012). 
Importantly, the molecular events that lead to JNK-dependent autophagy are not well 
understood. Moreover, the biological significance of JNK-mediated autophagy differs among 
various forms of stress.    
Our data shows upon adenoviral infection, JNK phosphorylates Bcl-2 and is required 
for the consequent dissociation of Bcl-2/beclin 1 complexes. Armed with our own and 
previously documented results, we expected JNK expression and activation is required for 
adenovirus-induced autophagy. We also anticipated JNK1 and JNK2 may have redundant roles 
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due to the data we obtained in the isogenic MEF cells; thus, both must be knocked-down in 
order to inhibit autophagy.  
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Results: 
 
JNK1 and JNK2 cooperate to stimulate autophagy in adenovirus-infected cells. We used the 
isogenic MEF cell lines to further evaluate the requirement of JNK1 and/or JNK2 in regulating 
adenovirus-mediated autophagy. JNK wt, JNK1 -/-, and JNK2 -/- MEF cells performed 
productive autophagy after adenoviral infection, according to the marked degradation of p62 
(Figure 17A). Remarkably, JNK1 alone was not required to induce adenovirus-dependent 
autophagy. This finding again differs from the accepted paradigm for starvation-induced 
autophagy (Wei et al., 2008). After adenoviral infection, knock-out of both JNK1 and JNK2 
expression in the MEF cells was required to prevent p62 degradation (Figure 17A). In addition, 
knock-out of c-Jun expression in MEF cells (c-Jun -/-) did not inhibit p62 degradation in 
adenovirus-infected MEF cells, thereby suggesting JNK-dependent activation of transcription 
through c-Jun is not required for adenovirus-mediated autophagy (Figure 17B). In order to 
validate our data, we used the classical, most definitive method for detecting autophagy in 
cells: visualization of autophagosomes via electron microscopy. JNK wt, JNK1 -/-, and JNK2 -
/- cells exhibited formation of abundant autophagic vacuoles (Figure 18A). A higher 
magnification of these vacuoles proved that they were in fact the double-membrane–bound 
vacuoles that are distinctive of autophagosomes (Figure 18B). On the contrary, the majority of 
JNK1/2 -/- MEF cells infected with adenovirus did not contain autophagosomes (Figure 18A). 
Upon meticulous examination and quantification of the infected cell population, 75% of 
adenovirus-infected JNK wt cells were positive for autophagosomes. Double knock-out of 
JNK1 and JNK2 isoforms resulted in greater than 50% reduction in the number of infected cells 
containing autophagosomes (Figure 18C).  
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Figure 17. Knock-out of both JNK1 and JNK2 isoforms, but not the substrate c-Jun, 
prevents productive autophagy during adenovirus infection. A, Wild-type, JNK1-/-, JNK2 -
/-, and JNK1/2 -/- MEF cells were infected with UV-inactivated or active AdWT adenovirus at 
an MOI of 100. Western blot was employed to analyze productive autophagy in whole cell 
lysates using anti-p62 antibodies. B, C-Jun KO (c-Jun -/-) MEFs were infected with UV-
inactivated or active AdWT adenovirus at an MOI of 100.  
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Figure 18. Knock-out of both JNK1 and JNK2 reduces autophagosome formation in 
adenovirus-infected cells. A, Wild-type, JNK1-/-, JNK2 -/-, and JNK1/2 -/- MEF cells were 
infected with UV-inactivated or active AdWT adenovirus at an MOI of 100 for 48h. Electron 
microscopy was utilized to visualize the double-lipid-bilayer-bound autophagic vacuoles that 
form during adenovirus-mediated autophagy. Images of whole cells(~6000X) and 
corresponding higher magnification intracellular regions (~25000X) for each cell line were 
collected to detect autophagosome formation. B, Representative high-magnification images of 
autophagic vacuoles in wild-type, JNK1 -/- and JNK2-/- MEFs are included. C, The number of 
wild-type and JNK1/2 -/- cells in infected samples was quantified manually from 5 fields (~45 
cells total). The graph represents the percentage of cells that were positive for autophagy above 
basal levels (>10 autophagosomes). 
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JNK isoforms regulate autophagy in adenovirus-infected cancer cells. We substantiated the 
results obtained in the isogenic MEF cell lines using small interfering RNAs (siRNA) that were 
specific for the JNK1 and JNK2 isoforms to directly target and down-modulate JNK expression 
in U87 MG cells. We were able to achieve approximately 80% knock-down of JNK isoforms 
(as detected by a pan-JNK antibody). As expected, U87 MG cells expressing non-coding 
siRNAs and infected with ∆24RGD adenovirus exhibited p62 degradation and LC3-I to LC3-II 
conversion. Consistent with our previous results, simultaneous down-regulation of JNK1 and 
JNK2 expression impaired adenovirus-mediated autophagy according to these markers (Figure 
19). 
 
JNK activation is required for adenovirus-mediated autophagy. JNK-mediated regulation of 
Bcl-2/beclin 1 interactions was facilitated by adenovirus-triggered JNK phosphorylation. Thus, 
JNK phosphorylation would be integral to the efficient regulation of autophagy in host cells.  
To examine this hypothesis, A549 cells were pre-treated with a chemical inhibitor selective for 
JNK phosphorylation, SP600125, prior to infection with adenovirus. We observed a decline in 
the p62 protein levels, indicating p62 degradation, and conversion of LC3-I to LC3-II 
suggesting productive autophagy occurred in A549 cells infected with adenovirus alone 
(Figure 20A). However, when these cells were pre-treated with SP600125 to inhibit JNK 
phosphorylation, autophagy was strikingly diminished (Figure 20A). These results suggest a 
critical role for JNK and Bcl-2 in the biochemical machinery that directs adenovirus-mediated 
autophagy. In order to determine the consistency of our data in various cell types and conclude 
that these phenomena apply to the oncolytic, tropism-enhanced ∆24RGD, we assessed the 
induction of autophagy after adenoviral infection in U87 MG cells (Figure 20B). Cells were 
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Figure 19. RNA interference of JNK1 and JNK2 isoforms reduces adenovirus-mediated 
autophagy. JNK1 and JNK2 expression was reduced by isoform-specific siRNA 
oligonucleotides combined and introduced into U87 MG cells. Non-coding siRNAs were used 
as controls. After 48 h, cells were infected with ∆24RGD adenovirus at an MOI of 50 for 36 h. 
LC3 conversion was analyzed for productive autophagy. Relative fold-change in LC3-II was 
determined by densitometry analysis. 
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Figure 20. Chemically inhibiting JNK phosphorylation blocks adenovirus-associated 
autophagy initiation. A, A549 cells were stably transfected to express increased levels of Bcl-
2. After pre-treatment with 25 µM SP600125 30 min, cells were infected with ∆24RGD 
adenovirus at an MOI of 50 for 48 h. Western blotting was performed with whole cell protein 
lysates to examine p62 degradation and LC3 conversion. B, U87 MG cells were transfected 
with an EGFP-LC3 vector. After 48h, cells were pre-treated with DMSO or SP600125 (25 µM) 
for 30 min prior to infection with ∆24RGD adenovirus at an MOI of 50 for 48h. GFP-LC3 
puncta formation was visualized upon induction of autophagy. Representative deconvolution 
microscopy images are depicted (left). C, The percentage of LC3-puncta positive cells (>10 
puncta) was determined by counting the total cells in 5 fields from three independent 
experiments. Statistical significance was determined using the Student’s t test (right). 
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transfected to over-express exogenous GFP-LC3. Under normal conditions, the GFP-LC3 was 
expressed ubiquitously throughout the cell. However, upon infection with adenovirus, the 
characteristic GFP-LC3 puncta formation indicates LC3-II insertion into the membrane of 
autophagic vacuoles. We observed this phenomenon in greater than 65% of the cells infected 
with ∆24RGD adenovirus, thereby confirming autophagy (Figure 20B). Importantly, GFP-LC3 
puncta formation was impaired in the majority of cells pre-treated with SP600125. Thus, the 
number of cells positive for autophagy was significantly reduced in cells pre-treated the JNK 
inhibitor (Figure 20B).  
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Conclusions: 
Our study yields new information about the biological significance of JNK pathway 
activation in adenovirus-mediated autophagy. Phosphorylation of both JNK and Bcl-2 was 
detected in vitro and in vivo upon adenovirus infection. Furthermore, expression and activation 
of JNK was required for Bcl-2 phosphorylation, release of Beclin 1, and the consequent 
induction of autophagy. Contrary to starvation which is dependent solely on JNK1, ablation of 
both JNK1 and JNK2 was required to inhibit adenovirus-mediated autophagy. In addition, 
knock-out of c-Jun expression did not inhibit p62 degradation in adenovirus-infected MEF 
cells, thereby suggesting JNK-dependent modifications in Bcl-2 phosphorylation regulate 
autophagy instead of JNK-dependent modification in transcription through c-Jun. We did not 
focus our studies on JNK3 because this isoform is expressed primarily in neurons and the heart 
(Martin et al., 1996; Gupta et al., 1996; Kuan et al., 1999). In agreement with this, although 
JNK3 was expressed at low levels in JNK1/2 -/- MEF cells (Figure 15), these cells were not 
able to undergoing productive autophagy. Thus, JNK3 likely has negligible effects upon 
adenovirus-induced autophagy based on the data we obtained. Our data suggested adenoviruses 
can utilize diverse host cell pathways to obtain their ultimate goal of cell lysis, and proposed a 
novel role for JNK2 in the regulation of autophagy that had not been described previously. 
Comprehending the mechanistic regulation of autophagy in response to adenovirus infection 
should provide the opportunity to assess prospective targets for combined chemotherapeutic 
strategies with the ∆24RGD adenovirus currently in a phase 1 clinical trial for the treatment of 
recurring malignant gliomas.  
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Chapter VII: JNK and autophagy facilitate presentation of adenoviral antigens. 
 
Rationale and Expectations: 
JNK has various roles within the cellular immune response machinery against viral 
infection. Cellular proteins (e.g. TLR9, Rig-1, OAS) recognize viral DNA and RNA and 
stimulate signaling through JNK for the expression of pro-inflammatory cytokines. (Ichijo H., 
1999; Johnson and Lapadat, 2002; Barton and Medzhitov, 2003; Minamitani et al., 2011). 
JNK pathway activation leads to expression and release of type 1 interferons, which are also 
powerful inducers of JNK signal transduction (Ichijo et al., 1997; Caraglia et al., 1999; Sung 
et al, 2001; Takada et al., 2005; Basner-Tschakarjan et al., 2006; Minamitani et al., 2011). 
However, there is a paucity of information regarding the role of JNK in the presentation of 
antigens and has not yet been investigated within the context of adenoviruses or autophagy. 
Autophagy is a well-documented mechanism of immune presentation of viral antigens 
(Figure 4). In addition to the direct sequestration and degradation of viruses, autophagy 
participates in the processing of antigens for presentation in major histocompatibility (MHC) 
molecules on the surface of infected cells (Crotzer and Blum, 2009; English et al. 2009; 
Paludan et al, 2005). Autophagy has been implicated in the processing of viral antigens 
primarily for presentation on MHC class II molecules (Münz et al., 2000; Paludan et al., 2005; 
Jaraquemada et al., 1990). Importantly, whether autophagy is required for the presentation of 
adenovirus antigens has not yet been examined. Thus, we hypothesized that adenovirus-
mediated autophagy is an anti-viral immune response: initiated by immune-related receptors, 
transduced by the JNK MAP kinase pathway, and concluded with the presentation of 
adenoviral epitopes to the immune system for further recruitment and activation of immune 
cells. We expected that JNK and autophagy would be essential to the display of adenoviral 
antigens at the surface of host cells; and thus, the consequent activation of immune cells. 
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Results: 
 
JNK is essential to the display of adenoviral antigens at the cell surface. In order to test our 
hypothesis, we designed an experiment to detect a variety of adenoviral epitopes on the surface 
of intact, live cells after infection for 48 hours. After using an antibody cocktail against several 
capsid antigens, we identified cells displaying adenoviral antigens by addition of fluorescent 
secondary antibodies and detection via flow cytometry. We observed greater than 13% of wild-
type MEF cells presented adenoviral antigens on the cell membrane after infection with AdWT 
(Figure 21). In contrast, the percentage of JNK1/2 -/- MEF cells presenting adenoviral antigens 
was hardly detectable (~2%). The mitigating effects of knocking-out JNK1 and JNK2 gene 
expression on the presentation of adenoviral eptiopes to the immune system were significant (p 
< 0.001) (Figure 21). Thus, JNK expression is required for efficient adenoviral antigen 
presentation. 
 
JNK regulates adenoviral antigen presentation for the activation of immune cells. Next, we 
verified that the display of adenoviral antigens on ∆24RGD-infected wild-type MEF cells could 
activate primed splenocytes; thus, confirming adenoviral epitopes are being presented by MHC 
molecules for activation of immune cells. Splenocytes were isolated from naïve and ∆24RGD-
immunized C57BL/6 mice, and then combined in culture with pre-infected JNK wt and JNK1/2 
-/- MEF cells. After 24 h of co-culture, we detected IFNγ in the culture medium as a well-
described marker of splenocyte activation (Figure 22A). Only the wild-type MEF cells pre-
infected with ∆24RGD were able to dramatically stimulate IFNγ production in splenocytes 
from immunized mice (primed) (Figure 22B). The MEF cells lacking JNK1 and JNK2 genes 
were deficient in activating the primed splenocytes; thus, ~75% less IFNγ was detected in the 
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Figure 21. JNK regulates the display of adenoviral antigens at the surface of host cells. A, 
Wild-type and JNK1/2 -/- MEF cells were infected with AdWT adenovirus at an MOI of 100 
for 48 h. Live cells were incubated with antibodies raised against a blend of adenoviral coat 
proteins. The cells were subsequently stained with APC-conjugated secondary antibodies and 
analyzed via flow cytometry. Mouse IgG was used as a control and propidium iodide was used 
to eliminate dead cells. The percentage of cells that display adenoviral coat antigens at the 
surface of the cell is represented in the graph. Statistical significance was determined using the 
Student’s t test.  
0.73 1.10 
0.25 0.97 
22.20 
2.05 
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Figure 22. Adenovirus-infected MEF cells require JNK expression in order to activate 
splenocytes from immunized mice. A, A schematic of the protocol detecting splenocyte 
activation is depicted. In brief, C57BL/6 mice were infected with 10
7 
pfu ∆24RGD adenovirus 
twice (Day 1 and 3) intracranially through a guide-screw method. The animals were euthanized 
on Day 14 and spleens were collected. In parallel, wild-type and JNK1/2 -/- cells were infected 
with an MOI of 100 for 24 h. Splenocytes from naïve and immunized mice were then co-
cultured with the pre-infected MEFs for 24 h. The levels IFNγ in the co-culture medium was 
detected using the Mouse IFN gamma ELISA kit. B, The graph represents the concentration of 
IFNγ (pg/ml) in the co-culture media, which is indicative of splenocyte activation. Statistical 
significance was determined using the Student’s t test.  
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culture medium of these cells (Figure 22B). Importantly, neither JNK wt nor JNK1/2 -/- pre-
infected with ∆24RGD could provoke IFNγ production in naïve splenocytes. In addition, mock 
infected JNK wt and JNK1/2 -/- could not stimulate primed splenocytes. This confirms the 
IFNγ is produced by the primed splenocytes only upon activation by infected cells that can 
efficiently present adenoviral antigens.  
 
Adenoviral antigens are processed and presented on MHC class II molecules. It remains 
elusive the extent to which adenoviral antigens are presented on MHC class I or MHC class II 
molecules and the role of JNK in this process. Thus, we infected JNK wt and JNK1/2 -/- MEF 
cells with ∆24RGD and incubated them with blocking antibodies against MHC class I or MHC 
class II.  Splenocytes from ∆24RGD-immunized C57BL/6 mice were then added for 24 hours 
and IFNγ production was detected in the co-cultured media as an indicator of splenocyte 
activation (Figure 23A). We detected a 30-fold increase in splenocyte activation by pre-
infected JNK wt MEF cells without blocking antibodies or with IgG (Figure 23B). Again, the 
JNK1/2 -/- cells exhibited a considerably deficient ability to activate splenocytes. Importantly, 
a significant decrease in IFNγ production was detected from splenocytes in co-culture with pre-
infected JNK wt and MHC class II blocking antibodies (Figure 23B). Conversely, splenocyte 
activation was not appreciably inhibited by MHC class I blocking antibodies. Therefore, our 
data suggest adenoviral antigens are presented on MHC class II molecules in a JNK-dependent 
manner.  
 
JNK-dependent autophagy is a mechanism of viral antigen processing. The data we collected 
in MEF cell lines were reproducible in U87 MG cells infected with ∆24RGD adenovirus in 
combination with the inhibitor of JNK phosphorylation, SP600125. After infection with 
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Figure 23. MHC class II-dependent adenoviral antigen presentation activates splenocytes 
from immunized mice. A, A schematic of the protocol detecting splenocyte activation is 
depicted. C57BL/6 mice were infected with 10
7
 pfu ∆24RGD adenovirus intracranially. 
Spleens were isolated on Day 14. In parallel, wild-type and JNK1/2 -/- MEFs were infected 
with an MOI of 100 for 24 h. The cells were washed and incubated with blocking antibodies to 
MHC class I or MHC class II molecules. IgG was used as a control. After 2 h, splenocytes from 
immunized mice were added for co-culture with the pre-infected MEFs and blocking antibodies 
for 24 h. The levels IFNγ in the co-culture medium was detected using the Mouse IFN gamma 
ELISA kit. B, The concentration of IFNγ (pg/ml) in the co-culture media is displayed 
graphically. Statistical significance was determined using the Student’s t test. 
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Figure 24. JNK activation and autophagy regulate the presentation of adenoviral antigens 
on cancer cells. U87 MG cells were pre-treated with DMSO, SP600125 (25 µM), or 
bafilomycin A1 (10 nM) for 30 min prior to infection with ∆24RGD adenovirus at an MOI of 
50 for 48 h. Live cells were incubated with a combination of antibodies raised against a blend 
of adenoviral coat proteins. Upon staining with an APC-conjugated secondary antibody, cells 
were analyzed by flow cytometry. A mouse IgG was included as a control, and dead cells were 
excluded by propidium iodide staining. APC-positive cells were quantified (upper right) and 
analyzed for statistical significance. Infected samples pre-treated with inhibitors were 
compared to those pre-treated with DMSO. Asterisks (*) indicate a pvalue of less than 0.05 
determined by a Student’s t test. 
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∆24RGD for 48 h, approximately 19% of cells displayed adenoviral capsid epitopes at their 
surface. A significant decrease (p = 0.02) in the number of cells presenting adenoviral antigens 
was observed after adenoviral infection was combined with the SP600125 inhibitor (Figure 
24). We next examined the effect on antigen presentation caused by blocking the autophagy 
flux.  In these studies, we used bafilomycin A1 (BA1), a well-characterized inhibitor of 
autophagy which prevents the fusion of autophagosomes with lysosomes (Yamamoto et al., 
1998). As expected, this halted the processing of antigens. We observed that the number of 
cells pre-treated with 10 nM BA1 that displayed adenoviral epitopes at the surface decreased 
significantly (Figure 24). Collectively, these data strongly suggest that both JNK and JNK-
regulated autophagy are part of the cellular processes leading to the efficient processing and 
presentation of adenoviral antigens in cells infected with adenoviruses. 
 
Rapamycin enhances adenoviral antigen presentation. Rapamycin activates autophagy 
through chemical inhibition of mTOR (Brown et al., 1994; Noda and Ohsumi, 1998). We 
combined treatment with rapamycin and infection with ∆24RGD adenovirus in order to 
determine the effect of combining an autophagy-promoter on adenoviral antigen presentation. 
After co-treatment for 48 hours, there was a significant increase in the display of adenoviral 
epitopes at the surface of U87 MG cells. Approximately 65% of cells presented adenoviral 
antigens after combination therapy, which was a 2-fold increase when compared to ∆24RGD 
alone (Figure 25). Our data confirm rapamycin enhances adenoviral antigen presentation and 
corroborate our discovery that autophagy regulates this process.   
 
Autophagy degrades viral proteins for antigen presentation on the surface of cells. Self and 
foreign proteins are degraded in autophagosomes in order to recycle basic components, as well 
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Figure 25. Rapamycin enhances adenoviral antigen presentation. U87 MG cells were pre-
treated with 100 nMrapamycin, an activator autophagy via mTOR inhibition. After 30 min, 
cells were infected with ∆24RGD at an MOI of 50 for 48 h. Cells were incubated with 
antibodies to a blend of adenoviral coat proteins followed by staining with APC-conjugated 
secondary antibodies. Live, APC-positive cells were detected by flow cytometry; dead cells 
were excluded by propidium iodide staining. The percentage of antigen-presenting cells are 
represented in the graph and compared for statistical significance using a Student’s t test.  
0.98 25.49 69.99 
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as to present peptides within MHC molecules at the surface of the cell for detection by the 
immune system (Klionsky et al., 2000; Crotzerand Blum, 2009; English et al., 2009; Paludan 
et al., 2005; Levine et al., 2011). Notably, autophagy-related protein 5 (Atg5) is required for 
the activation and maintenance of autophagy induced by various stimuli including adenovirus 
(Mizushima et al., 1998; Jiang et al., 2011). Thus, we used isogenic MEF cell lines in order to 
examine the role of autophagy in the degradation and presentation of adenoviral antigens to the 
immune system. First, we examined the ability for these isogenic cell lines to display 
adenoviral antigens on the cell surface. The data obtained in adenovirus-infected malignant 
glioma cells pre-treated with bafilomycin A1 (Figure 24) was confirmed in Atg5 -/- cells. 
While wild-type MEF cells presented adenoviral antigens on their surface (~15%), Atg5-/- cells 
displayed significantly less (p < 0.01) adenoviral epitopes (Figure 26). Next, we examined the 
protein levels of adenoviral fiber in wild-type Atg5 (Atg5 wt) and Atg5 knock-out (Atg5-/-) 
MEF cells via western blot. In agreement with the accepted paradigm of autophagy, we 
detected considerably less adenoviral fiber protein in Atg5 wt cells when compared to the 
levels of fiber in Atg5 -/- cells (Figure 27A). This data suggests that fiber is being degraded 
during productive autophagy in wild-type MEF cells, and this phenomenon is inhibited in the 
autophagy-deficient Atg5 -/- MEF cells. In agreement with this data, we discovered that p62, a 
chaperone protein selectively degraded in autophagosomes, binds to adenoviral fiber and hexon 
proteins in Atg5 wt and Atg5-/- cells (Figure 27B). Again, the protein levels of p62-bound fiber 
and hexon were much higher in the Atg5 knock-out cells. Of note, we confirmed that cells 
expressing wild-type Atg5 were able to undergo autophagy after adenoviral infection by 
detection of LC3-I to LC3-II conversion; however, the Atg5 knock-out MEF cells did not 
exhibit this marker (Figure 27B). Additionally, we used isogenic p62 MEF cells to confirm the 
role of p62 in the recruitment of adenoviral proteins for degradation and antigen presentation. 
Wild-type p62 MEF cells were able to present adenoviral antigens similar to the Atg5 wt cells.  
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Figure 26. Autophagy regulates the display of adenoviral epitopes at the surface of cells. 
A, Wild-type and Atg5 KO (Atg5-/-) MEF cells were infected with AdWT adenovirus at an 
MOI of 100 for 48 h. Live cells were incubated with a combination of antibodies raised against 
a blend of adenoviral coat proteins. After staining with APC-conjugated secondary antibodies, 
the cells were analyzed via flow cytometry. Mouse IgG was used as a control, and propidium 
iodide was used to exclude dead cells. B, The graph depicts the percentage of cells presenting 
adenoviral antigens. Statistical significance was determined using the Student’s t test.  
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Figure 27. P62 binds to adenoviral coat proteins for degradation and antigen presentation 
through autophagy. A, Wild-type and Atg5 KO (Atg5-/-) MEF cells were infected with AdWT 
adenovirus at an MOI of 50 for indicated times. Whole cell protein lysates were analyzed by 
western blot for adenoviral fiber expression.  B, Wild-type and Atg5 -/- MEF cells were 
infected with AdWT adenovirus at an MOI of 50 and cell lysates were prepared in IP lysis 
buffer. Lysates were incubated with antibodies to p62. Both p62-immunoprecipitated 
complexes and input (5%) samples were analyzed by western blotting for adenoviral hexon and 
fiber protein expression. C, Wild-type and p62 KO (p62 -/-) MEF cells were infected with 
AdWT adenovirus at an MOI of 100 for 48 h. Live cells were incubated with a blend of 
antibodies raised against adenoviral coat proteins. APC-conjugated secondary antibodies were 
used to examine cells by flow cytometry. Mouse IgG was used as a control, and propidium 
iodide was used to exclude dead cells. The percentage of cells that display adenoviral coat 
antigens is indicated at the top right corner of the histogram. Statistical significance was 
determined using the Student’s t test. 
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There was a highly significant decrease in the number of cells displaying adenoviral epitopes 
when p62 was genetically knocked-out (p62 -/-) (Figure 27C).  Interestingly, the inhibition of 
adenoviral antigen presentation in p62 -/- MEF cells (Figure 27C) was not as dramatic in Atg5 
-/- MEF cells (Figure 26), suggesting other chaperone proteins may be involved in the 
recruitment of adenoviral antigens, such as heat shock proteins (Dice, 2007). Taken together, 
our data suggests p62 may assist in the targeting of adenoviral proteins for degradation in 
autophagosomes resulting in the presentation of adenoviral antigens to the immune system. 
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Conclusions: 
 Here, we establish for the first time that infected cells present adenoviral antigens 
through the process of autophagy. In addition, our novel data clearly demonstrates JNK 
regulates adenoviral antigen presentation, possibly by autophagy-dependent and -independent 
mechanisms. Importantly, we confirm that the activation of immune cells by infected cells is 
dependent upon JNK-mediated adenoviral antigen presentation. Similar to other viruses that 
induce autophagy (Münz et al., 2000; Paludan et al., 2005; Jaraquemada et al., 1990), our data 
suggests adenoviruses also present antigens on MHC class II molecules at the cell surface. 
However, this is likely that adenoviral antigen presentation is both MHC class I- and MHC 
class II-dependent. We also observe autophagy-dependent p62 recruitment and consequent 
degradation of viral capsid proteins for presentation at the cell surface. As autophagy primarily 
degrades proteins and loads peptides onto MHC class II molecules for presentation, our results 
further establish the role of autophagy in adenoviral antigen presentation. Moreover, 
augmenting adenovirus-mediated autophagy through rapamycin-induced mTOR inhibition was 
able to drastically enhance the display of adenoviral antigens, which is significant to the 
development of adenoviral-based immunotherapeutic and combination strategies. 
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Chapter VIII: Delta-24-FvIII infection induces EGFRviii antigen presentation. 
 
Rationale and Expectations:  
Modulating the immune system using conditionally replicating, oncolytic adenoviruses 
is under investigation for the targeted treatment of cancer (Bridle et al, 2010). Evidence 
suggests recombinant adenoviruses expressing tumor-associated antigens can prime the 
environment for an immune response against tumor cells (Chen et al., 1996; Rosenberg et al., 
1998; Perricone et al., 2000; Sorensen et al., 2009). The first FDA-approved therapeutic 
cancer vaccine Provenge (Sipuleucel-T) activates patient’s immune cells by professional 
antigen presentation of prostatic acid phosphatase (PAP), which is selectively over-expressed in 
most prostate cancer cells. Provenge is currently being used for the treatment of castration-
resistant prostate cancer (Huber et al, 2012). 
Epidermal growth factor receptor (EGFR) is frequently up-regulated in cancer, 
particularly malignant gliomas, and the EGFR variant III (EGFRvIII) is an extremely prevalent, 
tumor-specific mutation (Moscatello et al., 1995). It is also a highly immunogenic protein; 
thus, it is considered a tumor-associated antigen that can be used in the development of 
immunotherapeutic approaches (Sampson et al., 2009). Our laboratory has previously 
investigated the efficacy of targeting EGFRvIII-expressing malignant gliomas (Piao et al., 
2009); however, using recombinant adenoviruses to harness and reprogram the immune system 
to attack EGFRvIII-expressing tumor cells has yet to be investigated. We hypothesized that an 
adenovirus expressing the immunogenic EGFRvIII epitope would prime immune cells against 
tumor cells which endogenously over-express this molecule. Specifically, we expected infected 
tumor cells will present the EGFRvIII antigen to the immune system by autophagy-dependent 
mechanisms that could be enhanced by stimulating the cellular immune response.  
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Results: 
 
The cancer-specific antigen, EGFRvIII, was inserted into adenoviral fiber to form a novel 
∆24FvIII adenovirus. Our data suggested that adenoviral fiber is recruited to autophagosomes 
by p62 and then degraded into peptides which are presented on the surface of cells. Thus, we 
developed an EGFRvIII-expressing, anti-tumor vaccine (termed ∆24FvIII) that encompasses a 
chimeric fiber protein with incorporation of the immunogenic EGFRvIII epitope 
(LEEKKGNYVVT; Sampson et al., 2009) in the HI-loop (Figure 28A). The 24-base pair 
deletion in the E1A gene sequence is included in order to enforce selective replication of the 
adenovirus in Rb-inactivated tumor cells, similar to the ∆24RGD adenovirus (Fueyo et al., 
2001; Fueyo et al., 2003). We established the successful insertion of the EGFRvIII peptide into 
the adenoviral fiber sequence by direct DNA sequencing, and western blot using a monoclonal 
antibody that was raised against this epitope specifically (termed L8A4). Our data indicates 
A549 cells infected with the novel ∆24FvIII adenovirus expressed high levels of the EGFRvIII 
peptide (Figure 28B). These cells did not express EGFRvIII endogenously or after infection 
with the ∆24 adenovirus lacking the EGFRvIII peptide. Furthermore, a mobility shift was 
visualized when detecting adenoviral fiber protein by western blotting, suggesting an increase 
in molecular weight caused by the insertion of the EGFRvIII epitope (Figure 28B). 
 
Infection with ∆24FvIII adenovirus results in presentation of the EGFRvIII antigen. We 
next examined the presentation of this peptide on the surface of infected cells, and the role of 
autophagy in this system. Wild-type and Atg5-/- MEF cells were infected in parallel with the 
∆24FvIII adenovirus. In concordance with our previous data, the Atg5 wt MEF cells displayed 
EGFRvIII epitopes on the cell surface. We detected ~62% of Atg5 wt cells displayed the  
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Figure 28. An immunogenic EGFRvIII epitope is inserted in the HI loop of the ∆24 
adenovirus fiber sequence.  A, The EGFRvIII epitope (LEEKKGNYVVT) was inserted into 
the HI loop of the ∆24 adenovirus fiber sequence by excision exonucleases as indicated by the 
schematic illustration. The novel oncolytic adenovirus ∆24FvIII was rescued in HEK293 cells. 
B, Expression of the chimeric fiber encompassing the EGFRvIII peptide was examined in A549 
cells infected with ∆24FvIII at an MOI of 40 for 48 h. Protein lysates were analyzed by western 
blot analysis using anti-adenoviral fiber or a monoclonal antibody (termed L8A4) raised against 
this specific EGFRvIII epitope. 
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Figure 29. ∆24FvIII infection induces presentation of the ectopic EGFRvIII antigen. Wild-
type and Atg5 -/- MEFs were infected with ∆24FvIII at an MOI 100 for 48 h. Live cells were 
first incubated with the monoclonal EGFRvIII antibody L8A4, followed by staining with FITC-
conjugated  secondary antibodies and analysis by flow cytometry. Mouse IgG was used as a 
control and propidium iodide staining was used to exclude dead cells. The percentage of cells 
displaying the EGFRvIII epitope is indicated at the top right corner of each histogram. The 
difference between infected wild-type and infected Atg5 -/- cells was statistically significant as 
determined by a Student’s t test. Asterisks (***) indicate a p value of less than 0.001.  
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tumor-associated EGFRvIII epitope on the cell surface (Figure 29). Due to the specificity of 
the L8A4 antibody, the percentage of cells we detected presenting EGFRvIII antigens is much 
higher than the percentage of cells we detected using non-specific antibodies to a blend of 
adenoviral epitopes. Importantly, we observed a highly significant decrease in the percentage of 
Atg5-/- MEF cells displaying EGFRvIII antigens (Figure 29). Additionally, HeLa cells infected 
with this adenovirus also exhibited EGFRvIII antigen presentation that was ablated upon 
inhibiting autophagy with bafilomycin A1 (BA1) (Figure 30, upper panel). To further illustrate 
the role of autophagy in presenting this antigen to the immune system, we combined interferon 
gamma (INFγ) treatment with ∆24FvIII infection to enhance the expression of MHC molecules 
within host cells. Interferon gamma dramatically increased the presentation of EGFRvIII 
epitopes on the surface of HeLa cells, when compared to cells either mock infected or infected 
with ∆24FvIII alone (Figure 30, lower panel). Importantly, the effects of both interferon and 
adenoviral-mediated autophagy were blocked by bafilomycin A1, suggesting autophagy plays a 
critical role in presenting foreign antigens in the cellular immune response to adenovirus. Our 
data also indicates the competence of the ∆24FvIII adenovirus as an anti-tumor vaccine by its 
innate ability to induce autophagy for the presentation of this immunogenic EGFRvIII epitope 
on cancer cells. 
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Figure 30. Bafilomycin A inhibits adenovirus-induced and IFNγ-enhanced antigen 
presentation. HeLa cells were infected with ∆24FvIII at an MOI of 40. After infection for 6 h, 
300 units/ml of INFγ was added to the cells. Bafilomycin A1 (BA1; 100 nM) was added to the 
culture 24 h post infection. Live cells were collected 48 h after infection and incubated with the 
L8A4 monoclonal antibody for EGFRvIII. Staining with FITC-conjugated secondary 
antibodies was followed by analysis via flow cytometry. Propidium iodide staining excluded 
dead cells. The graph represents the percentage of cells presenting EGFRvIII epitopes. 
Statistical significance between indicated samples was determined by a Student’s t test and is 
represented by asterisks: (**) indicates a p value of less than 0.01, while (*) indicates a p value 
of less than 0.05. 
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Conclusions: 
 We constructed a novel adenovirus expressing the immunogenic EGFRvIII epitope 
within the HI loop of adenoviral fiber protein in order to 1) confirm the data we obtained 
detecting antigen presentation of a blend of adenoviral capsid proteins using non-specific 
antibodies, and 2) develop an adenovirus that presents the tumor-associated EGFRvIII antigen 
on the surface of infected tumor cells; and thus, has the potential to initiate an anti-tumor 
immune response. We succeeded in detecting the display of EGFRvIII antigens on the host cell 
surface during infection with the ∆24FvIII adenovirus. In accordance with previous data, this 
phenomenon was prevented by bafilomycin A1, confirming the role of autophagy in the 
presentation of adenoviral-expressed antigens. Interestingly, IFNγ was able to enhance the 
display of EGFRvIII antigens, probably due to increased MHC class II expression (Giroux et 
al., 2003). However, bafilomycin A1 was also able to inhibit IFNγ-enhanced adenoviral antigen 
presentation suggesting once again that autophagy controls the presentation of adenoviral 
antigens on MHC class II molecules. Importantly, the data we collected previously showing 
activation of immune cells by ∆24RGD-infected MEF cells strongly supports that immune cells 
can be activated against the EGFRvIII antigen. Future experimentation will focus on the extent 
to which the EGFRvIII-targeted immune cells can elicit an anti-tumor immune response.  
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Chapter IX: List of Conclusions (Figure 31) 
1. Adenovirus infection does not activate autophagy through the archetypal pathway 
regulating starvation- and stress-induced autophagy. 
a. AMPKs are not appreciably phosphorylated and are not required for adenovirus-
mediated autophagy 
b. TSC2 is not required for adenovirus-induced autophagy. 
c. AKT and mTOR are highly phosphorylated, but fail to inhibit autophagy 
2. JNK pathway is active in cells infected with adenovirus.   
a. JNK and c-Jun are phosphorylated in numerous cell types and after infection 
with either wild-type or ∆24RGD adenovirus. 
b. JNK is phosphorylated in vivo. 
3. JNK phosphorylates Bcl-2 resulting in dissociation of Bcl-2/beclin 1 complexes. 
a. Bcl-2 is phosphorylated in vitro and in vivo. 
b. JNK expression and activation are required for adenovirus-induced Bcl-2 
phosphorylation. 
c. JNK1 and JNK2 regulate the dissociation of Bcl-2/beclin 1 heterodimers.  
4. JNK is essential to the induction of autophagy in adenovirus-infected cells. 
a. JNK expression and activation is required for adenovirus-induced autophagy. 
b. JNK1 and JNK2 have potentially over-lapping roles in the regulation of 
adenovirus-induced autophagy. 
c. JNK activation regulates the loss in cell viability of adenovirus-infected cells. 
5. JNK and autophagy regulate adenoviral antigen presentation. 
a. JNK expression is essential to the display of adenoviral antigens at the host cell 
surface and consequent activation of immune cells. 
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b. Adenoviral antigens are presented on MHC class II molecules. 
c. Autophagy regulates the presentation of adenoviral antigens. 
d. P62 recruits adenoviral proteins, particularly fiber, to autophagosomes for 
degradation into peptides. 
6. EGFRvIII antigens are presented on the surface of ∆24FvIII infected cells. 
a. An immunogenic EGFRvIII peptide is inserted into the HI loop of the 
adenoviral fiber sequence. 
b. The EGFRvIII epitope is expressed and presented on the surface of ∆24FvIII 
infected cells. 
c. Inhibiting autophagy prevents ∆24FvIII-induced and IFNγ-enhanced 
presentation of EGFRvIII antigens. 
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Figure 31. The role of JNK and autophagy in the adenoviral antigen presentation. 
Adenoviruses infect and replicate within the cell triggering JNK phosphorylation. JNK 
phosphorylates Bcl-2 resulting in the release of beclin 1, a key activator of autophagy. P62 
binds to adenoviral proteins being produced within the cell and recruits them to 
autophagosomes for degradation into peptides. Autophagosomes fuse with the MHC class II 
compartment (MIIC). Peptides are loaded onto MHC class II molecules for antigen 
presentation. Activators of this pathway (rapamycin or IFNγ) amplify antigen presentation. The 
∆24FvIII adenovirus infection results in presentation of EGFRvIII cancer-specific antigens. 
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Chapter X: Discussion 
Herein, we demonstrated a unique mechanism underlying the regulation of autophagy in 
adenovirus-infected cells. We utilized a wild-type adenovirus as well as a tumor-selective, 
oncolytic adenovirus termed ∆24RGD, which is currently in clinical testing for the targeted 
treatment of malignant brain tumors (Fueyo et al., 2003; Jiang et al., 2007). We infected a 
series of normal and cancer human cell lines and genetically engineered mouse embryo 
fibroblasts. In doing so, we established that adenoviral replication in host cells induced strong 
and sustained activation of the JNK signal transduction pathway that is required for adenovirus-
induced autophagy. We also show that activation of JNK is required for the autophagy-related 
processing of adenovirus antigens and their presentation on the cell surface. We believe that in 
the fullness of time these results may have important overtones for the development of 
adenovirus-based vaccines for infectious diseases and cancer. 
We initially sought to validate the preliminary data on recombinant adenoviruses 
reported by Ito and collaborators for our model system: glioma cells infected with a tropism-
enhanced adenovirus (Ito et al., 2006). They suggested that adenoviral infection is followed by 
the hypo-phosphorylation of mTOR 72 hours after infection, thus inducing autophagy (Ito et 
al., 2006). In this pioneer study, Ito and colleagues may be observing a decrease of mTOR 
phosphorylation during the host cell lysis. At this late stage, the expression and 
phosphorylation of proteins is irrelevant to explain cellular events that occur prior to cell death. 
Our present experiments and previous studies (Jiang et al., 2007; Jiang et al., 2011) showed 
that autophagy is detectable in cells as early as 36 hours after infection with adenoviruses. In 
this study, a time-dependent examination of AKT and mTOR phosphorylation showed that the 
AKT/mTOR pathway was activated 16 hours after infection with wild-type and ∆24RGD 
adenoviruses, and this activation was maintained up to 48 hours. We also did not observe 
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activation of AMPK, a common cause of mTOR inactivation in cells undergoing autophagy 
(Inoki et al., 2003; Kim et al., 2011; Codogno and Meijer, 2005). Furthermore, we showed that 
AMPK and TSC2 expression are not required for adenovirus-mediated initiation of autophagy. 
Thus, in our system, this archetypal pathway was likely not responsible for the dramatic 
induction of autophagy in adenovirus-infected cells.  
Our data showed that JNK activation was extremely amplified during adenoviral 
replication. Importantly, no noticeable change in the phosphorylation of other MAP kinases 
(e.g. ERK1/2) was observed, suggesting specificity. For the first time, we demonstrate Bcl-2 is 
phosphorylated during adenovirus infection, and that JNK is required for Bcl-2 phosphorylation 
in adenovirus-infected cells. In contrast to the accepted tenet of molecular events regulating 
starvation-induced autophagy (Wei et al., 2008), Bcl-2/beclin 1 complexes are deregulated by 
the activation of either JNK1 or JNK2 during adenovirus infection. It was also intriguing to see 
that both JNK1 and JNK2 proteins played a role in the adenovirus-mediated induction of 
autophagy, and that complete ablation of both isoforms was required to block autophagy 
initiation. These data suggest that JNK1 and JNK2 have overlapping roles in the regulation of 
adenovirus-mediated autophagy. Our results further differentiate adenovirus-induced autophagy 
from starvation-induced autophagy, and suggest that their activation of JNK is probably 
regulated at multiple levels with complex overlapping mechanisms.  
We initially hypothesized that adenoviral proteins activate JNK1 and JNK2 through 
interactions with upstream constituents of this signaling pathway in the host cell. According to 
a previous report, the adenoviral protein E1B-19K may directly interact with MAPK kinases 
MAPKK5 or MAPKK7 to trigger JNK phosphorylation (See and Shi, 1998). This preliminary 
study examined the phosphorylation of a downstream substrate of JNK, c-Jun, during 
adenovirus infection in the presence and absence of E1B-19K. However, c-Jun has been 
identified as the target of many MAP kinases such as ERK1/2 and p38 (Leppä et al., 1998; 
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Yamagishi et al., 2001); therefore, their data regarding the role of E1B-19K in adenovirus-
induced JNK activation remain inconclusive. Our attempts to corroborate these preliminary 
findings using specific antibodies to detect JNK phosphorylation during adenovirus infection in 
the presence and absence of E1B-19K were unsuccessful (data not shown). Furthermore, we 
infected cells with adenoviruses mutant for each individual early gene and discovered no single 
protein is required for activation of JNK during adenovirus infection. JNK activation was only 
prevented during infection with viruses lacking the E1A gene sequence (data not shown), which 
is required for all viral DNA replication, transcription and protein expression (Nevins et al., 
1979; Bayley and Mymryk, 1994). Ectopic over-expression of individual adenoviral proteins by 
plasmid transfection was also ineffective at activating endogenous JNK (data not shown).  
In addition, our laboratory examined several other potential stimuli regulating 
adenovirus-induced JNK activation. Adenoviruses, JNK, and autophagy are all involved in 
numerous, and often overlapping, stress-response pathways (e.g. ER stress, DNA damage, 
oxidative stress). First, we investigated key constituents of the ER stress response during 
adenovirus infection. We found little to no change in the phosphorylation of protein kinase 
RNA-like endoplasmic reticulum kinase (PERK) or inositol-requiring protein 1 (IRE-1) (data 
not shown), which are previously described activators of JNK during ER stress (Urano et al., 
2000; Nishitoh et al., 2002). Next, we examined the role of DNA damage response in 
adenovirus-induced JNK activation (Cuconati et al., 2003). Although we detected the markers 
of DNA damage, gamma histone 2AX (γH2AX) and phosphorylated Ataxia telangiectasia 
mutated (ATM) protein kinase, neither of these proteins were required for JNK activation 
during adenovirus infection (data not shown). Lastly, upon combining the antioxidant N-acetyl 
cysteine (Aggarwal et al., 2011) with adenovirus infection, we discovered reducing oxidative 
stress has no effect on JNK activation in infected cells (data not shown). Thus, although we 
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cannot completely rule out any of these pathways possibly linking adenovirus infection and 
JNK activation, the data we have collected suggests JNK is activated within host cells by other 
mechanisms. 
Upon discovering the role of JNK in antigen presentation, we hypothesized that 
adenovirus-mediated activation of JNK may be part of the innate immune response against the 
virus. Cellular receptors (e.g., TLR9) and proteins (e.g., Rig-1, OAS) are known to recognize 
adenoviral oligonucleotides in order to stimulate JNK-dependent transcription of pro-
inflammatory cytokines, including type 1 interferons (Ichijo H., 1999; Johnson and Lapadat, 
2002; Barton and Medzhitov, 2003; Basner-Tschakarjan et al, 2006; Minamitani et al., 2011). 
Type 1 interferons can also activate JNK signal transduction in an attempt to eradicate the 
infected cell by inducing apoptosis (Ichijo et al., 1997; Caraglia et al., 1999; Sung et al, 2001; 
Takada et al., 2005); although, adenoviruses have numerous mechanisms for blocking 
apoptosis downstream of JNK (Rao et al., 1992; White, 1993). Additionally, type 1 interferons 
lead to the up-regulation of 2′,5′-oligoadenylate synthetase (OAS) (Rutherford et al., 1988). 
OAS can recognize adenoviral double stranded RNAs and produces 2'-5' linked oligoadenylates 
which trigger activation of RNase L (Hovanessian et al., 1977, Zhou et al., 1993). Interestingly, 
artificial activation of RNase L by 2'-5' linked oligoadenylates has recently been shown to 
induce JNK-dependent Bcl-2 phosphorylation, Bcl-2/beclin 1 dissociation, and autophagy 
induction (Siddiqui et al., 2012). Therefore, JNK activation in adenovirus-infected cells may 
result from a multi-mechanistic process involving redundant activators from the cellular and 
viral repertoire that fight against and converge with the adenovirus initiative to control the host 
cell and thereby generate a favorable scenario for its replication and spread. Further 
investigation is required to determine the extent to which each of these pathways are involved 
in activating JNK for the purpose of inducing autophagy and antigen presentation.  
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Autophagy promotes cell lysis; and thus, is advantageous for the adenovirus (Jiang et 
al., 2011). However, it is a double-edged sword; as JNK-mediated autophagy also benefits the 
host through promotion of adenoviral antigen-presentation and consequent activation of 
immune cells against the virus. Although autophagy has been well-documented in adenovirus-
infected cells, its role in this specific scenario is not completely understood. For some RNA 
viruses, autophagosomes are “viral factories”; thus, autophagy is employed in the interest of 
virus survival (Wileman, 2006). This paradigm cannot be applied to adenoviruses which, unlike 
RNA viruses, are assembled in the nucleus (D'Halluin, 1995), and are thus physically distant 
from cytoplasmic autophagosomes. Autophagy is a critical pathway for the processing of 
antigens and facilitating their interaction with MHC molecules (Crotzer and Blum, 2009; 
Orvedahl and Levine, 2009; Lin et al., 2010). During autophagy, proteins are digested to 
generate peptides of the required length and with the required modification in the N terminus to 
bind MHC class II complexes (Paludan et al., 2005). In macrophages infected with herpes 
simplex virus type 1, autophagy facilitates the presentation of viral antigens in MHC class II 
molecules on the cell membrane (English et al., 2009). In agreement with this information, our 
data suggests adenoviral antigens are also processed via autophagy for presentation on MHC 
class II molecules at the cell surface.  
Our finding that adenovirus-infected cancer cells induce JNK/autophagy-dependent 
antigen presentation to the immune system is a significant one. Understanding this process 
resulted in the construction of a recombinant adenovirus encompassing an immunogenic 
peptide inserted in the adenoviral fiber protein sequence, the ∆24FvIII adenovirus. We 
demonstrated that ectopic expression of an EGFRvIII tumor-associated antigen by the 
adenovirus will lead to its display at the cell surface. Future research will examine the extent to 
which this virus induces an anti-tumor, particularly an anti-glioma, immune response in animal 
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models and in patients. Furthermore, future experimentation should include combinations of 
chemical stimulators of autophagy (rapamycin) with recombinant adenoviruses expressing 
cancer-specific antigens for enhanced tumor vaccination. Rapamycin was able to drastically 
enhance the display of adenoviral antigens, potentially through mTOR inhibition and 
consequent autophagy induction (Brown et al., 1994; Noda and Ohsumi, 1998). This small 
molecule inhibitor is under clinical investigation for the treatment of malignant gliomas alone 
and in combination with other chemical inhibitors of the AKT/mTOR pathway (Chang et al., 
2004; Galanis et al., 2005; Goudar et al., 2005; Reardon et al., 2010). Moreover, our 
laboratory has shown rapamycin combined with the ∆24RGD adenovirus enhances the in situ 
oncolytic effects (Alonso et al., 2008). Thus, there are implications for both oncolytic 
virotherapy and vaccine-based immunotherapy in combination with this compound to improve 
the clinical outcome of patients suffering from malignant gliomas.  
Adenoviruses have the innate ability to recruit immune cells to the site of infection 
(Tatsis et al., 2004). Treatment with targeted, oncolytic adenoviruses has the potential to 
directly lyse tumor cells as well as instigate a localized immune response at the site of the 
tumor (Jiang et al., 2007; Jiang et al., 2011; Jager et al., 2003). Designing recombinant 
adenoviruses expressing tumor-associated antigens enhances their prospective recognition by 
immune cells and consequent anti-tumor immunity (Rosenberg et al., 1998; Bendandi et al., 
1999; Gulley et al., 2002). Due to the mutability of the adenoviral genome, this therapeutic 
approach can easily be adapted to personalized medicine. Using the antigen expression profile 
of each patient’s tumor, we can administer a combination of recombinant adenoviruses 
expressing tumor-associated antigens that could increase the probability of positive clinical 
outcomes. 
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It is essential to understand the molecular events regulating adenovirus-induced cell 
lysis, as well as how the host cell triggers an antiviral immune response, so that we may 
leverage these pathways in the development of novel anti-cancer vaccines. The targeted, 
EGFRvIII-expressing adenovirus is a product of the information discovered by this 
investigation. It capitalizes upon the inherent network of interactions between the virus and 
host cell machinery. It has the potential to trigger an immune response against malignant 
gliomas in a high percentage of patients. This unique immunotherapeutic strategy aims to 
improve the currently fatal prognosis of malignant gliomas. 
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